



Article

[3+3]-Annulation of Cyclic Nitronates with Vinyl Diazoacetates: Diastereoselective Synthesis of Partially Saturated [1,2]Oxazino[2,3-*b*][1,2]oxazines and Their Base-Promoted Ring Contraction to Pyrrolo[1,2-*b*][1,2]oxazine Derivatives

Yulia A. Antonova ¹ , Yulia V. Nelyubina ², Sema L. Ioffe ¹ and Andrey A. Tabolin ^{1,*} 
¹ N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp. 47, Moscow 119991, Russia

² A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilov Str. 28, Moscow 119991, Russia

* Correspondence: tabolin87@mail.ru; Tel.: +7-499-135-53-29

Abstract: A rhodium(II)-catalyzed reaction of cyclic nitronates (5,6-dihydro-4*H*-1,2-oxazine *N*-oxides) with vinyl diazoacetates proceeds as a [3+3]-annulation producing bicyclic unsaturated nitroso acetals (4a,5,6,7-tetrahydro-2*H*-[1,2]oxazino[2,3-*b*][1,2]oxazines). Optimization of reaction conditions revealed the use of Rh(II) octanoate as the preferred catalyst in THF at room temperature, which allows the preparation of target products in good yields and excellent diastereoselectivity. Under basic conditions, namely, the combined action of DBU and alcohol, these nitroso acetals undergo ring contraction of an unsaturated oxazine ring into the corresponding pyrrole. Both transformations can be performed in a one-pot fashion, thus constituting a quick approach to oxazine-annulated pyrroles from available starting materials, such as nitroalkenes, olefins, and diazo compounds.

Keywords: [3+3]-annulation; diazo compounds; nitronates; 1,2-oxazines; pyrroles; rhodium carbenoids; nitrogen heterocycles



Citation: Antonova, Y.A.; Nelyubina, Y.V.; Ioffe, S.L.; Tabolin, A.A. [3+3]-Annulation of Cyclic Nitronates with Vinyl Diazoacetates: Diastereoselective Synthesis of Partially Saturated [1,2]Oxazino[2,3-*b*][1,2]oxazines and Their Base-Promoted Ring Contraction to Pyrrolo[1,2-*b*][1,2]oxazine Derivatives. *Molecules* **2023**, *28*, 3025. <https://doi.org/10.3390/molecules28073025>

Academic Editor: Richard A. Bunce

Received: 27 February 2023

Revised: 23 March 2023

Accepted: 24 March 2023

Published: 28 March 2023




Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

1,2-Oxazine derivatives represent an important class of nitrogen–oxygen heterocycles which are widely used in organic chemistry [1–8]. Reductive cleavage of the N–O bond makes 1,2-oxazine derivatives useful precursors to aminoalcohols and functionalized carbonyl compounds. Moreover, 1,2-oxazines are versatile substrates for the preparation of other important heterocyclic motifs, such as pyrrolidine, pyrrole, or furan. The recent growth of the research interest in the chemistry of 1,2-oxazines is promoted by the discovery of bioactive natural products possessing 1,2-oxazine core (Scheme 1, (1)) [9–18]. Such compounds as trichodermamides or phyllantidine became attractive targets for both total synthesis and preparation of analogues in pursuit of increased bioactivity [19–26].

One of the synthetic routes to 1,2-oxazines is based on various transformations of six-membered cyclic nitronates, 5,6-dihydro-4*H*-1,2-oxazine *N*-oxides **1** (Scheme 1, (2)). These substrates are readily accessible via the [4+2]-cycloaddition between such simple starting materials as conjugated nitroalkenes and olefins [27,28]. It allows a quick and stereoselective construction of an oxazine ring, while further transformations of the *N*-oxide moiety are used for the desired modifications of the assembled heterocyclic core. One of the most known and most used reactivity patterns of nitronates is the [3+2]-cycloaddition [28–31]. It leads to the assembly of annulated 6,5-bicyclic nitroso acetals, possessing six- and five-membered rings. For instance, this strategy was extensively exploited by Denmark and coworkers in the total synthesis of pyrrolizidine and indolizidine alkaloids [32–39]. In contrast to [3+2]-cycloaddition, other cycloaddition/annulation reactions of nitronates remain underexplored. Recently, we reported a formal [3+3]-cycloaddition reaction of

cyclic nitronates **1** with donor–acceptor cyclopropanes (DACs) [40,41]. DACs reacted as three-carbon components and allowed a smooth diastereoselective preparation of nitroso acetals, possessing two saturated oxazine rings. To expand the scope of polycyclic frameworks, which can be available from nitronates **1**, we pursued other three-carbon annulation partners. In continuation of these studies, we turned our attention to the vinyl diazoacetates **2**, which recommended themselves as useful 1,3-dipole equivalents in annulations leading to various carbocycles (cyclobutenes, cyclopentenones, etc.) and heterocycles (pyrazoles, pyrroles, isoxazolines, quinolines, etc.) [42,43]. Herein, we report the [3+3]-annulation of nitronates **1** with vinyl diazoacetates **2** for the synthesis of 6,6-bicyclic nitroso acetals **3** and their further transformation into pyrrole-annulated oxazine derivatives.




Scheme 1. Representative bioactive 1,2-oxazine derivatives (**1**) and synthesis of 1,2-oxazine derivatives via cycloaddition of cyclic nitronates **1** (**2**). *—chiral center.

2. Results and Discussion

We initiated our study with optimization of the reaction between model nitronate **1a** and vinyl diazoacetate **2a** (Table 1). Variations of catalyst, solvent, temperature, and reagent ratio were performed. Notably, only one diastereomer of adduct **3a** was detected in all experiments. Among the solvents tested, the best results were achieved in THF. In other ethereal solvents (diethyl ether, glyme, 1,4-dioxane), a decrease in yield was observed (Entries 2–4), while in acetonitrile, dichloromethane, and hexane, starting nitronate **1a** was not fully consumed (Entries 6–8). As compared to rhodium(II) octanoate, rhodium(II) catalysts (acetate, trifluoroacetate, tetramethyl-1,3-benzenedipropionate) gave

worse results (Entries 10–12), while other metal catalysts that are often used in carbenoid reactions [42,44–52] did not produce the target product at all (Entries 13–17). Variations of reagent ratios (Entries 18–20), concentration (Entry 21), and reaction temperatures (Entries 22–23) did not lead to improvement in yield. Therefore, the use of 2 equiv. of vinyl diazoacetate and 2 mol.% of rhodium(II) octanoate in THF at r.t. (Entry 1) was chosen for subsequent studies.

Table 1. Optimization of reaction conditions ¹.




Entry	Solvent	Diazo 2a, Equiv.	Catalyst (Equiv.)	Recovery of 1a, % ²	Yield of 3a, % ²
1	THF	2	Rh ₂ Oct ₄ (0.02)	0	85
2	Glyme	2	Rh ₂ Oct ₄ (0.02)	9	54
3	Et ₂ O	2	Rh ₂ Oct ₄ (0.02)	0	65
4	1,4-dioxane	2	Rh ₂ Oct ₄ (0.02)	0	62
5	EtOAc	2	Rh ₂ Oct ₄ (0.02)	0	66
6	MeCN	2	Rh ₂ Oct ₄ (0.02)	23	30
7	CH ₂ Cl ₂	2	Rh ₂ Oct ₄ (0.02)	28	31
8	Hexane	2	Rh ₂ Oct ₄ (0.02)	49	22
9	Tol	2	Rh ₂ Oct ₄ (0.02)	0	54
10	THF	2	Rh ₂ (OAc) ₄ (0.02)	0	74
11	THF	2	Rh ₂ (OAcF) ₄ (0.02)	19	7
12	THF	2	Rh ₂ (esp) ₂ ³	7	64
13	THF	2	Cu(MeCN) ₄ PF ₆ (0.05)	0	0
14	THF	2	CuOTf·½C ₆ H ₆ (2)	0	0
15	THF	2	AgSbF ₆ (5)	0	0
16	THF	2	Pd(OAc) ₂ (5)	4	0
17	THF	2	Pd(PPh ₃) ₄ (2)	49	0
18	THF	3	Rh ₂ Oct ₄ (0.02)	0	81
19	THF	1.5	Rh ₂ Oct ₄ (0.02)	4	68
20	THF	2	Rh ₂ Oct ₄ (0.01)	10	66
21 ⁴	THF	2	Rh ₂ Oct ₄ (0.02)	0	73
22 ⁵	THF	2	Rh ₂ Oct ₄ (0.02)	4	77
23 ⁶	THF	2	Rh ₂ Oct ₄ (0.02)	0	75

¹ Reactions were performed in 0.2 M solution of nitronate **1a** at r.t. for 1 day, unless otherwise mentioned.

² Determined by ¹H NMR with an internal standard (dimethyl terephthalate). ³ esp = α,α,α',α'-tetramethyl-1,3-benzenedipropionate. ⁴ Reaction was performed in 1 M solution. ⁵ Reaction was performed at 0 °C. ⁶ Reaction was performed at 50 °C for 4 h.

With the optimized conditions in hand, an evaluation of the substrate scope was performed (Scheme 2). Diazoacetates possessing various ester groups were successfully involved in the reaction. Alkyl (Me, **3b**; Et, **3c**), benzyl (**3d**), *p*-nitrobenzyl (**3e**), and phenyl (**3f**) esters gave corresponding products in good yields. However, better results were achieved for electron-accepting 2,2,2-trichloroethyl (**3a**) and *p*-nitrobenzyl (**3e**) moieties, which is in line with the previously reported advantages of these substituents in C–H functionalization and cyclopropanation [53–56]. Poor yields and/or conversions were observed for vinyl diazoacetates with bulky *tert*-butyl (**2g**) or BHT (2,6-di-*tert*-butyl-4-methylphenyl, **2h**) ester groups [57]. Unfortunately, complex mixtures were observed when employing substituted (β-phenyl or γ-phenyl) vinyl diazoacetates. Regarding the scope of nitronates **1**, the reaction tolerates various aryl groups at the C4 of starting nitronate. *Meta*-(**3i**)- and *para*-(**3a,g,h**)-substituted substrates gave products **3** smoothly, while for *ortho*-substituent

(3j) a diminished yield was attained, presumably, due to steric hindrance. Importantly, no influence of the electronic effect of aromatic substituent was observed as electron-accepting (NO_2 , **3h**), halogen (**3g,j**), as well as pharmaceutically attractive dihydroxylated aromatics [58,59] (**3k**) gave comparable outcomes. Apart from aryl-, 5-benzoyloxy-(**3l**), 5-alkyl-(**3m**), and 7-ethoxy-(**3o**) products were obtained, thus demonstrating the possibility of incorporation of different functionalities in the target structures. Poor yield was attained for cyclohexane-annulated product **3p**, while a complex product mixture was observed for nitronate **1q**. When more sterically encumbered camphene-derived (**1r**) or 3-methyl-substituted nitronate (**1s**) was involved, the reaction was decelerated and starting materials were observed even after 4 days.



Scheme 2. Synthesis of bicyclic nitroso acetals **3**.

Structures of the obtained products were supported by their NMR (1D and 2D) and HRMS data. Gratifyingly, in all examined cases, the annulation was found to be stereoselective producing only one diastereomer of products **3**. The relative configuration of stereocenters was also deduced on the basis of the coupling constant between C(4a)-H and C(5)-H. Its high value of 9–11 Hz evidenced about (pseudo)axial positions of both protons. This conclusion was supported by the X-ray analysis for products **3b** and **3p** (Figure 1). No-

tably, the *cis*-junction of two oxazine rings was observed, which can be favored by anomeric interaction within O–N–O moiety [60]. However, we should mention the conformational lability of products **3**, as many signals in their NMR spectra were broadened. Especially notable was product **3p** possessing three contiguous annulated six-membered rings. In its case, a lot of the ^{13}C signals were of low intensity and were assigned only with the aim of ^1H - ^{13}C HSQC spectra (see Supplementary Materials). Mentioned effects can be attributed to both inversion of six-membered rings and to nitrogen inversion [41,61].





Figure 1. General view of the compounds **3b** (left) and **3p** (right) in the representation of non-hydrogen atoms as thermal ellipsoids at a 30% probability level.

Based on the obtained and the literature [42,43,62] data, the following mechanism for the annulation was proposed (Scheme 3). In the first step, electrophilic vinyl carbenoid species **A** is generated from vinyl diazo compound **2** and a rhodium catalyst. Nucleophilic attack of the oxygen atom of *N*-oxide at the unhindered $=\text{CH}_2$ terminus in **A** produces zwitterion **B** that undergoes ring closure with the expulsion of the catalyst and formation of target cycloadduct (path a). Observed stereochemistry can be explained by an approach of the bulky vinyl-rhodium moiety from the face of the dipole opposite to substituent R^1 . Hence, low yields in the case of product **3p** and the messy reaction for nitronate **1q** can be attributed to the presence of a relatively bulky substituent at C(6) of the nitronate, which together with the substituent at C(4) may block both sides of the dipole, thus preventing the annulation. Interestingly, the observed [3+3]-annulation with nitronates differs from the reaction of vinyl diazoacetates with nitrones, which often proceeds via a [3+2]-pathway and subsequent carbene reactions (cf. path b) [63–66], while the respective [3+3]-pathway was rarely observed [62].


Aiming at the subsequent functionalization of product **3b**, we attempted a Michael addition of dimethyl malonate across the $\text{C}=\text{C}$ double bond. However, none of the desired transformation was observed, albeit ring contraction occurred providing pyrrolo[1,2-*b*]oxazine derivative **4b**. This process has some precedents in the literature [67–75], with the closest analogue observed by Kerr et al. for non-annulated oxazines under the treatment with DBU in MeCN [67]. The proposed mechanism starts with the deprotonation at C(2), which is facilitated by the conjugation of the formed anion with $\text{C}=\text{C}-\text{CO}_2$ moiety in **D** (Scheme 4). Subsequent cleavage of the N–O bond, formation of an aldehyde group, and recyclization produce hydroxypyrroline **E**, upon which dehydration furnishes the target pyrrole ring (path a). Some optimization of reaction conditions was performed (Scheme 5) and a combination of base (DBU) and protic additive (alcohol) was found optimal, instead of the use of a base alone (cf. yields for DBU and DBU/TCEOH). We attribute it to two main reasons. First, N–O bonds in nitroso acetals are also susceptible to basic cleavage (e.g., Scheme 4, path b) [76,77], which can lead to the formation of side products. The use of alcohol promotes the elimination of the hydroxyl group from intermediate **E** via

hydrogen bonding, thus facilitating pyrrole formation (path a). Secondly, the presence of alcohol diminishes the amount of carboxylic acid **5**, which originates from the hydrolysis of product **4a** by water. Particularly, relatively large amounts of product **5** were observed when a strong base, namely, sodium *tert*-butylate was used. Similarly, in the excess of methanol, transesterification was observed (Scheme 6).


The literature provides limited data on the preparation of pyrrolo[1,2-*b*]oxazine derivatives [78,79], especially possessing an unsaturated pyrrole core [80,81]. Therefore, we elucidated the scope of the found transformation. Since the reagents used for the [3+3]-annulation should not interfere with the ring contraction, we decided to make a one-pot protocol for the synthesis of pyrrolooxazines **4** from oxazine *N*-oxides **1** and vinyl diazoacetates **2**. For this purpose, the reaction mixture was evaporated after the annulation step and redissolved in CH₂Cl₂, followed by the addition of other reagents. This worked well providing target products **4** in reasonable yields for the whole two-step sequence (Scheme 7).




Scheme 3. Proposed reaction mechanism for the [3+3]-annulation of **1** and **2**.




Scheme 4. Proposed mechanism for the ring contraction of **3** and formation of pyrrolooxazines **4**. Substituents are omitted for clarity.



Scheme 5. Transformations of nitroso acetal **3a** in basic conditions (see Supplementary Materials for full details). Yields were determined by ¹H NMR with an internal standard (dimethyl terephthalate).
¹ Isolated yield.



Scheme 6. Formation of pyrrole **4b** from nitroso acetal **3a** by sequential ring contraction/transesterification.



Scheme 7. One-pot synthesis of pyrrolo[1,2-*b*]oxazines **4**.

3. Materials and Methods

3.1. General Experiment

All reactions were performed in oven-dried (150 °C) glassware. Most of the chemicals were acquired from commercial sources (Sigma-Aldrich, St. Louis, MO, USA; Acros Organics, Geel, Belgium; Alfa Aesar, Heysham, UK; ABCR, Karlsruhe, Germany; and P&M Invest, Moscow, Russia) with purities >95% and used as received. Petroleum ether (PE) and ethyl acetate were distilled. THF, CH₃CN, CH₂Cl₂, and DBU were distilled from CaH₂. Brine refers to the saturated aqueous solution of NaCl. TLC was performed on silica coated on aluminum with UV254 indicator. Visualization was accomplished with UV and/or anisaldehyde/H₂SO₄/EtOH stain. Column chromatography was performed on silica (0.04–0.063 mm, 60 Å). NMR spectra were recorded at 300 K (unless otherwise mentioned) on Bruker AM300 (Bruker, Karlsruhe, Germany), Fourier 300HD (Bruker, Karlsruhe, Germany), and Avance NEO (Bruker, Karlsruhe, Germany) spectrometers at the following spectrometer frequencies: 300 MHz (¹H NMR) and 75 MHz (¹³C NMR). Multiplicities are assigned as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad), and app (apparent). Assignment (including rel. configuration) was made using 2D NMR spectra for selected products. For other products, the assignment was made by analogy. High-resolution mass spectra were acquired on Bruker micrOTOF (Bruker, Bremen, Germany) spectrometer using electrospray ionization (ESI). Melting points were determined on a Koffler melting point apparatus and are uncorrected. Starting nitroalkenes [82–86], nitronates **1** [40,87–89], and vinyl diazoacetates **2** [55,90–97] were prepared according to the literature (see Supplementary Materials for detailed procedures).

3.2. X-ray Crystallography

X-ray diffraction data for **3b**, **3p**, and **4b** were collected at 100 K with a Bruker Quest D8 CMOS diffractometer (Bruker, Karlsruhe, Germany), using graphite-monochromated Mo-K α radiation (λ = 0.71073 Å, ω -scans). Structures were solved using Intrinsic Phasing with the ShelXT [98] structure solution program in Olex2 [99] and then refined with the XL refinement package [100] using Least-Squares minimization against F² in the anisotropic approximation for non-hydrogen atoms. Positions of other hydrogen atoms were calculated, and they were refined in the isotropic approximation within the riding model. Crystal data and structure refinement parameters are given in Table S1 (see Supplementary Materials). The crystallographic information for compounds **3b**, **3p**, and **4b** was deposited in the Cambridge Crystallographic Data Centre (CCDC 2242307–2242309) and can be obtained free of charge via <https://www.ccdc.cam.ac.uk/structures/> (accessed on 25 February 2023).

3.3. Synthetic Procedures for Products 3–5

3.3.1. General Procedure for the Synthesis of Nitroso Acetals **3** (GP-1)

To the 0.3 M solution of nitronate **1** (1 equiv.) in THF, Rh₂(Oct)₄ (0.02 equiv.) was added under an argon atmosphere at r.t. and the mixture was stirred for 5 min. Then THF solution of vinyl diazoacetate **2** (2 equiv. rel. to nitronate **1**, C = 0.5 M) was added dropwise (approx. 5–10 min.) using a syringe with stirring. The resulting solution was left overnight and then evaporated. The residue was preadsorbed onto Celite® or silica gel and subjected to column chromatography on silica gel (eluent: PE/EtOAc or PE/CH₂Cl₂) to give target nitroso acetal **3**.

2,2,2-Trichloroethyl (4aR*,5S*)-5-(4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate **3a**. Nitroso acetal **3a** was obtained from nitronate **1a** (24 mg, 0.10 mmol) and vinyl diazoacetate **2a** (50 mg, 0.21 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 10:1) afforded 39 mg (85%) of the target nitroso acetal **3a** as colorless oil, which solidified upon storage in a fridge (ca. 4 °C). *R*_f = 0.30 (PE/EtOAc, 5:1, UV, anisaldehyde). m.p. = 112–114 °C (EtOAc). ¹H NMR (300 MHz, CDCl₃): δ 1.38 (s, 3H, Me(7)), 1.63 (s, 3H, Me(7)), 1.92 (dd, *J* = 13.3, 3.1 Hz, 1H, CH_{2eq}(6)), 2.24 (app t, *J* = 12.9 Hz, 1H, CH_{2ax}(6)), 3.50 (ddd, *J* = 13.4, 10.5, 3.1 Hz, 1H, CH(5)), 3.80 (s, 3H, OMe), 4.05–4.09 (m, 2H, OCH_{2a}CCl₃ and CH(4a)), 4.39 (d, *J* = 11.9 Hz, 1H, OCH_{2b}CCl₃),

4.55 (dd, $J = 18.1, 3.5$ Hz, 1H, CH_{2a}(2)), 4.80 (br d, $J = 18.1$ Hz, 1H, CH_{2b}(2)), 6.83 (d, $J = 8.7$ Hz, 2H, CH_{Ar}), 6.95 (dd, $J = 3.2, 1.5$ Hz, 1H, CH(3)), 7.18 (d, $J = 8.7$ Hz, 2H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 28.7 (Me(7)), 30.8 (Me(7)), 36.3 (CH(5)), 41.2 (CH₂(6)), 55.3 (OMe), 65.1 (CH(4a)), 68.5 (CH₂(2)), 73.8 (OCH₂CCl₃), 79.1 (C(7)), 94.7 (CCl₃), 113.7 (CH_{Ar}), 129.6 (CH_{Ar}), 130.4 and 132.0 (C(4) and CH_{Ar}), 138.6 (=CH(3)), 158.7 (C_{Ar}–OMe), 162.8 (C=O). HRMS (ESI): m/z calcd. for C₁₉H₂₃Cl₃NO₅⁺ [M + H]⁺: 450.0636, found: 450.0649.

Methyl (4aR,5S*)-5-(4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3b.* Nitroso acetal **3b** was obtained from nitronate **1a** (24 mg, 0.10 mmol) and vinyl diazoacetate **2b** (50 mg, 0.21 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 10:1) afforded 20 mg (59%) of the target nitroso acetal **3b** as colorless oil, which solidified upon storage in a fridge (ca. 4 °C). $R_f = 0.59$ (PE/EtOAc, 1:1, UV, anisaldehyde). m.p. = 131–133 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, COSY, CDCl₃): δ 1.37 (s, 3H, Me_{eq}(7)), 1.62 (s, 3H, Me_{ax}(7)), 1.90 (dd, $J = 13.3, 3.1$ Hz, 1H, CH_{2eq}(6)), 2.24 (app t, $J = 13.1$ Hz, 1H, CH_{2ax}(6)), 3.19 (s, 3H, CO₂Me), 3.47 (ddd, $J = 12.8, 10.5, 2.7$ Hz, 1H, CH(5)), 3.80 (s, 3H, OMe), 4.01 (dd, $J = 10.5, 1.5$ Hz, 1H, CH(4a)), 4.49 (dd, $J = 17.8, 3.3$ Hz, 1H, CH_{2a}(2)), 4.75 (br d, $J = 17.8$ Hz, 1H, CH_{2b}(2)), 6.77 (dd, $J = 3.3, 1.4$ Hz, 1H, CH(3)), 6.84 (d, $J = 8.7$ Hz, 2H, CH_{Ar}), 7.16 (d, $J = 8.7$ Hz, 2H, CH_{Ar}). Characteristic NOESY interactions: CH(5)/CH_{2eq}(6); CH_{2ax}(6)/CH(4a); CH_{2ax}(6)/CH_{Ar}; CH(4a)/CH_{Ar}; Me_{ax}(7)/CH(5). ¹³C NMR (75 MHz, DEPT, HSQC, HMBC, CDCl₃): δ 28.6 (Me(7)), 30.9 (Me(7)), 36.3 (CH(5)), 41.1 (CH₂(6)), 51.5 (CO₂Me), 55.3 (OMe), 65.4 (CH(4a)), 68.5 (CH₂(2)), 78.9 (C(7)), 113.6 (CH_{Ar}), 129.4 (CH_{Ar}), 131.6 and 132.3 (C(4) and CH_{Ar}), 136.4 (=CH(3)), 158.6 (C_{Ar}–OMe), 165.4 (C=O). HRMS (ESI): m/z calcd. for C₁₈H₂₄NO₅⁺ [M + H]⁺: 334.1649, found: 334.1645. The crystallographic information for compound **3b** was deposited in the Cambridge Crystallographic Data Centre (CCDC 2242307).

4-Ethyl (4aR,5S*)-5-(4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3c.* Nitroso acetal **3c** was obtained from nitronate **1a** (21 mg, 0.09 mmol) and vinyl diazoacetate **2c** (25 mg, 0.18 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 10:1, then 8:1) afforded 18 mg (58%) of the target nitroso acetal **3c** as colorless oil, which solidified upon storage in a fridge (ca. 4 °C). $R_f = 0.30$ (PE/EtOAc, 3:1, UV, anisaldehyde). m.p. = 132–134 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, CDCl₃): δ 1.02 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃), 1.37 (s, 3H, Me(7)), 1.62 (s, 3H, Me(7)), 1.90 (dd, $J = 13.2, 3.0$ Hz, 1H, CH_{2eq}(6)), 2.23 (app t, $J = 13.1$ Hz, 1H, CH_{2ax}(6)), 3.39–3.35 (m, 2H, CH(5) and OCH_{2a}CH₃), 3.72–3.83 (m, 1H, OCH_{2b}CH₃), 3.79 (s, overlapped, 3H, OMe), 4.03 (dd, $J = 10.6, 1.4$ Hz, 1H, CH(4a)), 4.50 (dd, $J = 17.7, 3.4$ Hz, 1H, CH_{2a}(2)), 4.75 (br d, $J = 17.7$ Hz, 1H, CH_{2b}(2)), 6.75 (d, $J = 3.1, 1.4$ Hz, 1H, CH(3)), 6.83 (d, $J = 8.7$ Hz, 2H, CH_{Ar}), 7.16 (d, $J = 8.7$ Hz, 2H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 13.9 (OCH₂CH₃), 28.6 (Me(7)), 30.9 (Me(7)), 36.3 (CH(5)), 41.2 (CH₂(6)), 55.3 (OMe), 60.6 (OCH₂CH₃), 65.3 (CH(4a)), 68.4 (CH₂(2)), 79.0 (C(7)), 113.6 (CH_{Ar}), 129.5 (CH_{Ar}), 131.9 and 132.3 (C_{Ar} and C(4)), 135.9 (=CH(3)), 158.7 (C_{Ar}–O), 165.0 (C=O). HRMS (ESI): m/z calcd. for C₁₉H₂₆NO₅⁺ [M + H]⁺: 348.1805, found: 348.1805.

Benzyl (4aR,5S*)-5-(4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3d.* Nitroso acetal **3d** was obtained from nitronate **1a** (29 mg, 0.13 mmol) and vinyl diazoacetate **2d** (47 mg, 0.25 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 15:1) afforded 37 mg (73%) of the target nitroso acetal **3d** as slightly yellow oil. Analytically pure material was obtained after crystallization from PE/CH₂Cl₂ (1:1) as white powder. $R_f = 0.62$ (PE/EtOAc, 1:1, UV, anisaldehyde). m.p. = 110–112 °C (PE/CH₂Cl₂, 1:1). ¹H NMR (300 MHz, CDCl₃): δ 1.36 (s, 3H, Me(7)), 1.62 (s, 3H, Me(7)), 1.90 (dd, $J = 13.3, 3.1$ Hz, 1H, CH_{2eq}(6)), 2.22 (app t, $J = 13.1$ Hz, 1H, CH_{2ax}(6)), 3.49 (ddd, $J = 13.3, 10.5, 3.1$ Hz, 1H, CH(5)), 3.80 (s, 3H, OMe), 4.07 (app d, $J = 10.3$ Hz, 1H, CH(4a)), 4.38 (d, $J = 12.5$ Hz, 1H, OCH_{2a}Ph), 4.50 (dd, $J = 17.8, 3.5$ Hz, 1H, CH_{2a}(2)), 4.73–4.82 (m, 2H, CH_{2b}(2) and OCH_{2b}Ph), 6.78–6.81 (m, 3H, CH_{Ar} and CH(3)), 7.14–7.19 (m, 4H, CH_{Ar}), 7.32–7.38 (m, 3H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 28.7 (Me(7)), 30.9 (Me(7)), 36.3 (CH(5)), 41.2 (CH₂(6)), 55.3 (OMe), 65.3 (CH(4a)), 66.2 (OCH₂Ph),

68.5 (CH₂(2)), 79.0 (C(7)), 113.7 (CH_{Ar}), 128.0 (CH_{Ph}), 128.1 (CH_{Ph}), 128.4 (CH_{Ph}), 129.5 (CH_{Ar}), 131.6 and 132.2 (C_{Ar} and C(4)), 135.6 (C_{Ph}), 136.6 (=CH(3)), 158.6 (C_{Ar}-O), 164.7 (C=O). HRMS (ESI): *m/z* calcd. for C₂₄H₂₈NO₅⁺ [M + H]⁺: 410.1962, found: 410.1964.

4-Nitrobenzyl (4aR*,5S*)-5-(4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3e. Nitroso acetal **3e** was obtained from nitronate **1a** (35 mg, 0.15 mmol) and vinyl diazoacetate **2e** (73 mg, 0.30 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 7:1, then 5:1) afforded 48 mg (72%) of the target nitroso acetal **3e** as colorless oil, which solidified upon storage in a fridge (*ca.* 4 °C). *R_f* = 0.52 (PE/EtOAc, 1:1, UV, anisaldehyde). *m.p.* = 140–142 °C (EtOAc). ¹H NMR (300 MHz, CDCl₃): δ 1.37 (s, 3H, Me(7)), 1.62 (s, 3H, Me(7)), 1.90 (dd, *J* = 13.3, 2.9 Hz, 1H, CH_{2eq}(6)), 2.21 (app t, *J* = 13.1 Hz, 1H, CH_{2ax}(6)), 3.49 (ddd, *J* = 13.3, 10.5, 3.1 Hz, 1H, CH(5)), 3.76 (s, 3H, OMe), 4.06 (app d, *J* = 10.6 Hz, 1H, CH(4a)), 4.46 (d, *J* = 13.5 Hz, 1H, OCH_{2a}Ar), 4.53 (dd, *J* = 18.0, 3.5 Hz, 1H, CH_{2a}(2)), 4.78 (d, *J* = 18.0 Hz, 1H, CH_{2b}(2)), 4.93 (d, *J* = 13.5 Hz, 1H, OCH_{2b}Ar), 6.73 (d, *J* = 8.6 Hz, 2H, CH_{Ar}OMe), 6.87 (br s, 1H, CH(3)), 7.13 (d, *J* = 8.6 Hz, 2H, CH_{Ar}OMe), 7.29 (d, *J* = 8.7 Hz, 2H, CH_{Ar}NO₂), 8.20 (d, *J* = 8.7 Hz, 2H, CH_{Ar}NO₂). ¹³C NMR (75 MHz, DEPT, HSQC, CDCl₃): δ 28.6 (Me(7)), 30.8 (Me(7)), 36.3 (CH(5)), 41.2 (CH₂(6)), 55.2 (OMe), 64.8 (OCH₂Ar), 65.2 (CH(4a)), 68.5 (CH₂(2)), 79.1 (C(7)), 113.6 (CH_{Ar}OMe), 123.7 (CH_{Ar}NO₂), 128.2 (CH_{Ar}NO₂), 129.5 (CH_{Ar}OMe), 131.1 and 132.2 (C_{Ar}OMe and C(4)), 137.7 (=CH(3)), 142.9 (C_{Ar}NO₂), 147.6 (C_{Ar}-NO₂), 158.6 (C_{Ar}-O), 164.4 (C=O). HRMS (ESI): *m/z* calcd. for C₂₄H₂₇N₂O₇⁺ [M + H]⁺: 455.1813, found: 455.1807.

Phenyl (4aR*,5S*)-5-(4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3f. Nitroso acetal **3f** was obtained from nitronate **1a** (30 mg, 0.13 mmol) and vinyl diazoacetate **2f** (47 mg, 0.25 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 20:1, then 9:1) afforded 68 mg of crude nitroso acetal, which was crystallized from PE/CH₂Cl₂, 1:1 to give 34 mg (68%) of the target nitroso acetal **3f** as white powder. *R_f* = 0.30 (PE/EtOAc, 3:1, UV, anisaldehyde). *m.p.* = 175–176 °C (PE/CH₂Cl₂, 1:1). ¹H NMR (300 MHz, CDCl₃): δ 1.39 (s, 3H, Me(7)), 1.66 (s, 3H, Me(7)), 1.95 (dd, *J* = 13.2, 3.1 Hz, 1H, CH_{2eq}(6)), 2.26 (app t, *J* = 13.1 Hz, 1H, CH_{2ax}(6)), 3.58 (ddd, *J* = 13.3, 10.5, 3.0 Hz, 1H, CH(5)), 3.79 (s, 3H, OMe), 4.18 (dd, *J* = 10.5, 1.9 Hz, 1H, CH(4a)), 4.59 (dd, *J* = 18.0, 3.4 Hz, 1H, CH_{2a}(2)), 4.85 (dt, *J* = 18.0, 1.9 Hz, 1H, CH_{2b}(2)), 6.54–6.59 (m, 2H, CH_{Ph}), 6.85 (d, *J* = 8.7 Hz, 2H, CH_{Ar}), 7.01 (dd, *J* = 3.4, 1.9 Hz, 1H, CH(3)), 7.12–7.18 (m, 1H, CH_{Ph}), 7.22–7.28 (m, 4H, CH_{Ar} and CH_{Ph}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 28.7 (Me(7)), 30.9 (Me(7)), 36.4 (CH(5)), 41.4 (CH₂(6)), 55.3 (OMe), 65.2 (CH(4a)), 68.6 (CH₂(2)), 79.2 (C(7)), 114.1 (CH_{Ar}), 121.3 (CH_{Ph}), 126.6 (CH_{Ph}), 129.0 and 129.6 (CH_{Ar} and CH_{Ph}), 131.2 and 132.2 (C_{Ar} and C(4)), 138.1 (=CH(3)), 150.2 (C_{Ph}-O), 158.8 (C_{Ar}-O), 163.1 (C=O). HRMS (ESI): *m/z* calcd. for C₂₃H₂₆NO₅⁺ [M + H]⁺: 396.1805, found: 396.1806.

2,2,2-Trichloroethyl (4aR*,5S*)-5-(4-chlorophenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3g. Nitroso acetal **3g** was obtained from nitronate **1b** (35 mg, 0.15 mmol) and vinyl diazoacetate **2a** (72 mg, 0.30 mmol) according to GP-1. Column chromatography (eluent: PE/CH₂Cl₂, 1:1, then CH₂Cl₂) afforded 54 mg (80%) of the target nitroso acetal **3g** as colorless oil, which solidified upon storage in a fridge (*ca.* 4 °C). *R_f* = 0.48 (PE/EtOAc, 3:1, UV, anisaldehyde). *m.p.* = 121–123 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, CDCl₃): δ 1.38 (s, 3H, Me(7)), 1.63 (s, 3H, Me(7)), 1.93 (dd, *J* = 13.2, 3.0 Hz, 1H, CH_{2eq}(6)), 2.24 (app t, *J* = 13.2 Hz, 1H, CH_{2ax}(6)), 3.55 (ddd, *J* = 13.3, 10.5, 3.1 Hz, 1H, CH(5)), 4.06–4.12 (m, overlapped, 1H, CH(4a)), 4.13 (d, overlapped, *J* = 11.9 Hz, 1H, OCH_{2a}CCl₃), 4.42 (d, *J* = 11.9 Hz, 1H, OCH_{2b}CCl₃), 4.56 (dd, *J* = 18.2, 3.5 Hz, 1H, CH_{2a}(2)), 4.81 (app d, *J* = 18.2 Hz, 1H, CH_{2b}(2)), 7.00 (dd, *J* = 3.5, 1.7 Hz, 1H, CH(3)), 7.20–7.28 (m, 4H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 28.6 (Me(7)), 30.8 (Me(7)), 36.8 (CH(5)), 40.9 (CH₂(6)), 64.7 (CH(4a)), 68.5 (CH₂(2)), 73.8 (OCH₂CCl₃), 78.9 (C(7)), 94.6 (CCl₃), 128.5 (CH_{Ar}), 130.0 (CH_{Ar} and C(4)), 133.0 (C_{Ar}), 138.5 (C_{Ar}), 139.3 (=CH(3)), 162.7 (C=O). HRMS (ESI): *m/z* calcd. for [C₁₈H₂₀Cl₄NO₄]⁺ [M + H]⁺: 454.0141, found: 456.0145.

2,2,2-Trichloroethyl (4aR*,5S*)-7,7-dimethyl-5-(4-nitrophenyl)-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate 3h. Nitroso acetal **3h** was obtained from nitronate **1c** (27 mg, 0.11 mmol) and vinyl diazoacetate **2a** (55 mg, 0.23 mmol) according to GP-1.

Column chromatography (eluent: PE/EtOAc, 20:1, then 15:1) afforded 38 mg (78%) of the target nitroso acetal **3h** as colorless oil. $R_f = 0.36$ (PE/EtOAc, 3:1, UV, anisaldehyde). NB: Even on short standing in solution in CDCl_3 , decomposition of compound **3h** was observed. ^1H NMR (300 MHz, CDCl_3): δ 1.40 (s, 3H, Me(7)), 1.64 (s, 3H, Me(7)), 1.96 (dd, $J = 13.2, 2.6$ Hz, 1H, $\text{CH}_{2\text{eq}}(6)$), 2.30 (app t, $J = 13.1$ Hz, 1H, $\text{CH}_{2\text{ax}}(6)$), 3.71 (br t, $J = 12.3$ Hz, 1H, CH(5)), 4.14 (br d, $J = 10.7$ Hz, 1H, CH(4a)), 4.22 (d, $J = 11.9$ Hz, 1H, $\text{OCH}_{2\text{a}}\text{CCl}_3$), 4.33 (d, $J = 11.9$ Hz, 1H, $\text{OCH}_{2\text{b}}\text{CCl}_3$), 4.59 (dd, $J = 18.3, 3.2$ Hz, 1H, $\text{CH}_{2\text{a}}(2)$), 4.83 (app d, $J = 18.3$ Hz, 1H, $\text{CH}_{2\text{b}}(2)$), 7.09 (br s, 1H, CH(3)), 7.46 (d, $J = 8.6$ Hz, 2H, CH_{Ar}), 8.15 (d, $J = 8.7$ Hz, 2H, CH_{Ar}). ^{13}C NMR (75 MHz, DEPT, CDCl_3): δ 28.6 (Me(7)), 30.8 (Me(7)), 37.5 (CH(5)), 40.8 ($\text{CH}_2(6)$), 64.1 (CH(4a)), 68.6 ($\text{CH}_2(2)$), 73.8 (OCH_2CCl_3), 78.7 (C(7)), 94.5 (CCl_3), 123.4 (CH_{Ar}), 129.1 (C(4)), 129.6 (CH_{Ar}), 140.4 ($=\text{CH}(3)$ and C_{Ar}), 147.1 (C_{Ar}), 162.5 (C=O). HRMS (ESI): m/z calcd. for $\text{C}_{18}\text{H}_{20}\text{Cl}_4\text{NO}_4^+ [\text{M} + \text{H}]^+$: 454.0141, found: 456.0145.

2,2,2-Trichloroethyl (4aR*,5S*)-5-(3-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate **3i**. Nitroso acetal **3i** was obtained from nitronate **1d** (33 mg, 0.14 mmol) and vinyl diazoacetate **2a** (68 mg, 0.28 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 20:1, then 15:1) afforded 47 mg (76%) of the target nitroso acetal **3i** as slightly yellow oil, which solidified upon storage in a fridge (ca. 4 °C). $R_f = 0.30$ (PE/EtOAc, 5:1, UV, anisaldehyde). m.p. = 107–109 °C (PE/ CH_2Cl_2 , 2:1). ^1H NMR (300 MHz, CDCl_3): δ 1.38 (s, 3H, Me(7)), 1.63 (s, 3H, Me(7)), 1.95 (dd, $J = 13.3, 3.1$ Hz, 1H, $\text{CH}_{2\text{eq}}(6)$), 2.28 (app t, $J = 13.1$ Hz, 1H, $\text{CH}_{2\text{ax}}(6)$), 3.54 (ddd, $J = 13.3, 10.5, 3.1$ Hz, 1H, CH(5)), 3.81 (s, 3H, OMe), 4.03 (d, $J = 11.9$ Hz, 1H, $\text{OCH}_{2\text{a}}\text{CCl}_3$), 4.10 (d, $J = 10.5$ Hz, 1H, CH(4a)), 4.40 (d, $J = 11.9$ Hz, 1H, $\text{OCH}_{2\text{b}}\text{CCl}_3$), 4.56 (dd, $J = 18.1, 3.5$ Hz, 1H, $\text{CH}_{2\text{a}}(2)$), 4.81 (app d, $J = 18.1$ Hz, 1H, $\text{CH}_{2\text{b}}(2)$), 6.76–6.81 (m, 2H, CH_{Ar}), 6.87 (d, $J = 7.7$ Hz, 1H, CH_{Ar}), 6.97 (dd, $J = 3.5, 1.7$ Hz, 1H, CH(3)), 7.22 (app t, $J = 7.7$ Hz, 1H, CH_{Ar}). ^{13}C NMR (75 MHz, DEPT, CDCl_3): δ 28.6 (Me(7)), 30.8 (Me(7)), 37.2 (CH(5)), 40.7 ($\text{CH}_2(6)$), 55.2 (OMe), 64.9 (CH(4a)), 68.5 ($\text{CH}_2(2)$), 73.7 (OCH_2CCl_3), 79.0 (C(7)), 94.7 (CCl_3), 112.5 (CH_{Ar}), 114.5 (CH_{Ar}), 120.9 (CH_{Ar}), 129.4 (CH_{Ar}), 130.4 (C(4)), 138.6 ($=\text{CH}(3)$), 141.6 (C_{Ar}), 159.6 ($\text{C}_{\text{Ar}}-\text{OMe}$), 162.8 (C=O). HRMS (ESI): m/z calcd. for $\text{C}_{19}\text{H}_{23}\text{Cl}_3\text{NO}_5^+ [\text{M} + \text{H}]^+$: 450.0636, found: 450.0642.

2,2,2-Trichloroethyl (4aR*,5S*)-5-(2-chlorophenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate **3j**. Nitroso acetal **3j** was obtained from nitronate **1e** (28 mg, 0.12 mmol) and vinyl diazoacetate **2a** (57 mg, 0.24 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 40:1) afforded 32 mg (60%) of the target nitroso acetal **3j** as colorless oil, which solidified upon storage in a fridge (ca. 4 °C). $R_f = 0.51$ (PE/EtOAc, 3:1, UV, anisaldehyde). m.p. = 147–149 °C (PE/ CH_2Cl_2 , 2:1). ^1H NMR (300 MHz, CDCl_3): δ 1.38 (s, 3H, Me(7)), 1.67 (br s, 3H, Me(7)), 1.88 (dd, $J = 13.2, 2.7$ Hz, 1H, $\text{CH}_{2\text{eq}}(6)$), 2.22 (app t, $J = 13.0$ Hz, 1H, $\text{CH}_{2\text{ax}}(6)$), 4.10–4.16 (m, 2H, CH(4a) and $\text{OCH}_{2\text{a}}\text{CCl}_3$), 4.36–4.46 (m, 2H, CH(5) and $\text{OCH}_{2\text{b}}\text{CCl}_3$), 4.60 (dd, $J = 18.2, 3.3$ Hz, 1H, $\text{CH}_{2\text{a}}(2)$), 4.81 (app d, $J = 18.6$ Hz, 1H, $\text{CH}_{2\text{b}}(2)$), 7.00 (br s, 1H, CH(3)), 7.13–7.19 (m, 1H, CH_{Ar}), 7.27–7.32 (m, 2H, CH_{Ar}), 7.13–7.44–7.47 (m, 1H, CH_{Ar}). ^{13}C NMR (75 MHz, DEPT, CDCl_3): δ 28.7 (Me(7)), 30.7 (Me(7)), 32.1 (br, CH(5)), 41.2 ($\text{CH}_2(6)$), 64.5 (CH(4a)), 68.5 ($\text{CH}_2(2)$), 73.7 (OCH_2CCl_3), 78.9 (C(7)), 94.7 (CCl_3), 126.9 (CH_{Ar}), 128.1 (CH_{Ar}), 129.1 (C(4)), 129.5 (CH_{Ar}), 129.8 (CH_{Ar}), 134.4 (C_{Ar}), 137.6 (C_{Ar}), 139.6 ($=\text{CH}(3)$), 162.8 (C=O). HRMS (ESI): m/z calcd. for $\text{C}_{18}\text{H}_{20}\text{Cl}_4\text{NO}_4^+ [\text{M} + \text{H}]^+$: 454.0141, found: 454.0136.

2,2,2-Trichloroethyl (4aR*,5S*)-5-(3-(cyclopentylloxy)-4-methoxyphenyl)-7,7-dimethyl-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate **3k**. Nitroso acetal **3k** was obtained from nitronate **1f** (36 mg, 0.11 mmol) and vinyl diazoacetate **2a** (54 mg, 0.22 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 20:1, then 15:1) afforded 44 mg (73%) of the target nitroso acetal **3k** as colorless oil. $R_f = 0.46$ (PE/EtOAc, 3:1, UV, anisaldehyde). ^1H NMR (300 MHz, CDCl_3): δ 1.38 (s, 3H, Me(7)), 1.63 (br s, 3H, Me(7) and $\text{CH}_{2\text{cycl}}$), 1.80–2.01 (m, 7H, 3 \times $\text{CH}_{2\text{cycl}}$ and $\text{CH}_{2\text{eq}}(5)$), 2.21 (app t, $J = 13.1$ Hz, 1H, $\text{CH}_{2\text{ax}}(6)$), 3.46 (ddd, $J = 13.3, 10.5, 3.1$ Hz, 1H, CH(5)), 3.83 (s, 3H, OMe), 4.07 (dd, $J = 10.5, 1.9$ Hz, 1H, CH(4a)), 4.16 (d, $J = 12.0$ Hz, 1H, $\text{OCH}_{2\text{a}}\text{CCl}_3$), 4.37 (d, $J = 12.0$ Hz, 1H, $\text{OCH}_{2\text{b}}\text{CCl}_3$), 4.56 (dd, $J = 18.0, 3.3$ Hz, 1H, $\text{CH}_{2\text{a}}(2)$), 4.77–4.83 (m, 2H, $\text{CH}_{2\text{b}}(2)$ and $\text{CH}_{\text{cycl}}-\text{O}$), 6.75–6.78

(m, 3H, CH_{Ar}), 6.94 (dd, *J* = 3.3, 1.4 Hz, 1H, CH(3)). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 24.1 and 24.2 (2 × CH_{2cycl}), 28.7 (Me(7)), 30.9 (Me(7)), 32.88 and 32.92 (2 × CH_{2cycl}), 36.7 (CH(5)), 41.1 (CH₂(6)), 56.2 (OMe), 65.1 (CH(4a)), 68.5 (CH₂(2)), 73.7 (OCH₂CCl₃), 79.1 (C(7)), 80.5 (CH_{cycl}-O), 94.8 (CCl₃), 111.8 (CH_{Ar}), 115.5 (CH_{Ar}), 120.6 (CH_{Ar}), 130.6 (C(4)), 132.4 (C_{Ar}), 138.2 (=CH(3)), 147.6 (C_{Ar}-O), 149.2 (C_{Ar}-O), 162.6 (C=O). HRMS (ESI): *m/z* calcd. for C₂₄H₃₁Cl₃NO₆⁺ [*M* + *H*]⁺: 534.1211, found: 534.1196.

2,2,2-Trichloroethyl (4a*S,5*R**)-5-(benzoyloxy)-7,7-dimethyl-4a,5,6,7-tetrahydro-2*H*-[1,2]oxazino[2,3-*b*][1,2]oxazine-4-carboxylate 3l.** Nitroso acetal **3l** was obtained from nitronate **1g** (34 mg, 0.14 mmol) and vinyl diazoacetate **2a** (68 mg, 0.28 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 10:1) afforded 48 mg of crude nitroso acetal **3l** as colorless oil. Then, column chromatography (eluent: PE/CH₂Cl₂, 1:1, then CH₂Cl₂) afforded 40 mg (63%) of the target nitroso acetal **3l** as colorless oil. *R*_f = 0.50 (PE/EtOAc, 3:1, UV, anisaldehyde). ¹H NMR (300 MHz, 320 K, COSY, CDCl₃): δ 1.42 (s, 3H, Me), 1.63 (br s, 3H, Me), 1.98 (dd, *J* = 12.8, 10.3 Hz, 1H, CH_{2a}(6)), 2.20–2.40 (br m, 1H, CH_{2b}(6)), 4.29 (d, *J* = 9.3 Hz, 1H, CH(4a)), 4.52–4.85 (m, 4H, OCH₂CCl₃ and CH₂(2)), 5.80–5.91 (br m, 1H, CH(5)), 7.11–7.22 (m, 1H, CH(3)), 7.46 (app t, *J* = 7.5 Hz, 2H, CH_{Ph}), 7.58 (app tt, *J* = 7.4, 2.1 Hz, 1H, CH_{Ph}), 8.05 (app d, *J* = 7.2 Hz, 2H, CH_{Ph}). ¹³C NMR (75 MHz, 320 K, DEPT, HSQC, HMBC, CDCl₃): δ 29.3 (Me), 30.4 (br, Me), 40.4 (br, CH₂(6)), 62.0 (CH(4a)), 67.9 (CH(5)), 74.1 (OCH₂CCl₃), 81.2 (CH(7)), 94.7 (CCl₃), 128.4 (CH_{Ph}), 129.8 (CH_{Ph} and C_{Ph}), 133.2 (CH_{Ph}), 140.0 (=CH(3)), 162.9 (C=O), 165.8 (C=O). CH₂(2) and C(4) were not observed due to broadening/low intensity. ¹H NMR (300 MHz, 343 K, COSY, DMSO-*d*₆): δ 1.35 (s, 3H, Me_{eq}), 1.50 (br s, 3H, Me_{ax}), 1.95 (dd, *J* = 13.0, 9.7 Hz, 1H, CH_{2ax}(6)), 2.15–2.27 (br m, 1H, CH_{2eq}(6)), 4.15 (d, *J* = 8.3 Hz, 1H, CH(4a)), 4.62–4.65 (m, 2H, CH₂(2)), 4.77 (s, 2H, OCH₂CCl₃), 5.77 (app td, *J* = 9.1, 4.1 Hz, 1H, CH(5)), 7.20 (br s, 1H, CH(3)), 7.53 (app t, *J* = 7.6 Hz, 2H, CH_{Ph}), 7.67 (app tt, *J* = 7.4, 1.3 Hz, 1H, CH_{Ph}), 7.95 (app d, *J* = 7.1 Hz, 2H, CH_{Ph}). Characteristic NOESY interactions: Me_{ax}/CH(5); CH_{2eq}(6)/CH(5); CH_{2ax}(6)/CH(4a); Me_{eq}/CH_{2ax}(6). ¹³C NMR (75 MHz, 343 K, DEPT, HSQC, HMBC, DMSO-*d*₆): δ 29.6 (2 × Me), 39.8 (CH₂(6)), 61.9 (CH(4a)), 67.3 (br, CH₂(2)), 68.3 (CH(5)), 74.0 (OCH₂CCl₃), 80.6 (br, CH(7)), 95.5 (CCl₃), 126.8 (br, C(4)), 129.1 (CH_{Ph}), 129.7 (CH_{Ph}), 130.0 (C_{Ph}), 133.9 (CH_{Ph}), 141.4 (=CH(3)), 163.1 (C=O), 165.5 (C=O). HRMS (ESI): *m/z* calcd. for C₁₉H₂₁Cl₃NO₆⁺ [*M* + *H*]⁺: 464.0429, found: 464.0437.

2,2,2-Trichloroethyl (4a*R,5*R**)-7,7-dimethyl-5-phenethyl-4a,5,6,7-tetrahydro-2*H*-[1,2]oxazino[2,3-*b*][1,2]oxazine-4-carboxylate 3m.** Nitroso acetal **3m** was obtained from nitronate **1h** (31 mg, 0.13 mmol) and vinyl diazoacetate **2a** (63 mg, 0.26 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 30:1, then 20:1) afforded 43 mg (72%) of the target nitroso acetal **3m** as colorless oil, which solidified upon storage in a fridge (*ca.* 4 °C). *R*_f = 0.47 (PE/EtOAc, 3:1, UV, anisaldehyde). *m.p.* = 136–138 °C (EtOAc). ¹H NMR (300 MHz, COSY, CDCl₃): δ 1.32 (s, 3H, Me(7)), 1.53 (s, 3H, Me(7)), 1.53–1.59 (m, 2H, PhCH₂CH_{2a} and CH_{2ax}(6)), 1.63–1.75 (m, 1H, PhCH₂CH_{2b}), 2.03 (dd, *J* = 13.3, 2.7 Hz, 1H, CH_{2eq}(6)), 2.36–2.52 (m, 2H, CH(5) and PhCH_{2a}), 2.79 (ddd, *J* = 13.8, 10.6, 5.3 Hz, 1H, PhCH_{2b}), 3.87 (app d, *J* = 10.2 Hz, 1H, CH(4a)), 4.49 (dd, *J* = 18.4, 3.1 Hz, 1H, CH_{2a}(2)), 4.71–4.81 (m, 2H, OCH_{2a}CCl₃ and CH_{2b}(2)), 4.87 (d, *J* = 12.0 Hz, 1H, OCH_{2b}CCl₃), 7.10–7.31 (m, 6H, CH(3) and CH_{Ph}). ¹³C NMR (75 MHz, DEPT, HSQC, CDCl₃): δ 28.9 (Me(7)), 30.4 (CH(5)), 30.8 (Me(7)), 32.6 (PhCH₂), 33.6 (PhCH₂CH₂), 40.5 (CH₂(6)), 64.5 (CH(4a)), 68.4 (br, CH₂(2)), 74.1 (OCH₂CCl₃), 78.8 (C(7)), 94.8 (CCl₃), 125.9 (CH_{Ph}), 128.3 (CH_{Ph}), 128.4 (CH_{Ph}), 129.8 (C(4)), 140.5 (=CH(3)), 141.8 (C_{Ar}), 163.6 (C=O). HRMS (ESI): *m/z* calcd. for C₂₀H₂₅Cl₃NO₄⁺ [*M* + *H*]⁺: 448.0844, found: 448.0847.

2,2,2-Trichloroethyl (4a*R,5*S**,7*R**)-5,7-diphenyl-4a,5,6,7-tetrahydro-2*H*-[1,2]oxazino[2,3-*b*][1,2]oxazine-4-carboxylate 3n.** Nitroso acetal **3n** was obtained from nitronate **1i** (30 mg, 0.12 mmol) and vinyl diazoacetate **2a** (58 mg, 0.24 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 10:1) afforded 49 mg (88%) of the target nitroso acetal **3n** as colorless oil. Analytically pure material was obtained after crystallization from PE/CH₂Cl₂, 3:1 as white powder. *R*_f = 0.51 (PE/EtOAc, 3:1, UV, anisaldehyde). *m.p.* = 128–129 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, COSY, CDCl₃): δ 2.22 (app dt,

$J = 13.5, 3.2$ Hz, 1H, CH_{2eq}(6)), 2.48 (app q, $J = 12.6$ Hz, 1H, CH_{2ax}(6)), 3.65 (ddd, $J = 12.5, 10.7, 3.4$ Hz, 1H, CH(5)), 3.97 (d, $J = 11.9$ Hz, 1H, OCH_{2a}CCl₃), 4.33 (dd, $J = 10.7, 1.9$ Hz, 1H, CH(4a)), 4.42 (d, $J = 11.9$ Hz, 1H, OCH_{2b}CCl₃), 4.70 (dd, $J = 18.1, 3.4$ Hz, 1H, CH_{2a}(2)), 4.96 (dt, $J = 18.1, 1.8$ Hz, 1H, CH_{2b}(2)), 5.62 (dd, $J = 11.8, 2.5$ Hz, 1H, CH(7)), 7.02 (dd, $J = 3.4, 1.8$ Hz, 1H, CH(3)), 7.23–7.51 (m, 10H, 2 × Ph). Characteristic NOESY interactions: CH(7)–CH_{2eq}(6), CH(7)–CH(5), CH(4a)–CH_{2ax}(6), CH(5)–CH_{2eq}(6). ¹³C NMR (75 MHz, DEPT, HSQC, CDCl₃): δ 36.7 (CH₂(6)), 41.6 (CH(5)), 64.6 (CH(4a)), 68.8 (CH₂(2)), 73.7 (OCH₂CCl₃), 74.1 (CH(7)), 94.7 (CCl₃), 126.8 (CH_{Ph}), 127.4 (CH_{Ph}), 128.4 (CH_{Ph}), 128.48 (CH_{Ph}), 128.51 (CH_{Ph}), 128.6 (CH_{Ph}), 130.5 (C(4)), 138.7 (=CH(3)), 139.2 (C_{Ph}), 139.8 (C_{Ph}), 162.7 (C=O). HRMS (ESI): m/z calcd. for C₂₂H₂₁Cl₃NO₄⁺ [M + H]⁺: 468.0531, found: 468.0527.

2,2,2-Trichloroethyl (4aR*,5S*,7S*)-7-ethoxy-5-(4-methoxyphenyl)-4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate **3o**. Nitroso acetal **3o** was obtained from nitronate **1j** (26 mg, 0.10 mmol) and vinyl diazoacetate **2a** (51 mg, 0.21 mmol) according to GP-1. Column chromatography (eluent: PE/EtOAc, 20:1, then 10:1) afforded 34 mg (70%) of the target nitroso acetal **3o** as colorless oil. $R_f = 0.45$ (PE/EtOAc, 3:1, UV, anisaldehyde). ¹H NMR (300 MHz, COSY, CDCl₃): δ 1.27 (t, $J = 7.1$ Hz, 3H, OCH₂CH₃), 2.11 (ddd, $J = 13.4, 3.3, 1.2$ Hz, 1H, CH_{2eq}(6)), 2.45 (td, $J = 13.4, 4.1$ Hz, 1H, CH_{2ax}(6)), 3.55–3.75 (m, 2H, CH(5) and OCH_{2a}CH₃), 3.79 (s, 3H, OMe), 4.05–4.19 (m, 3H, OCH_{2a}CCl₃, CH(4a), and OCH_{2b}CH₃), 4.37 (d, $J = 11.9$ Hz, 1H, OCH_{2b}CCl₃), 4.55 (dd, $J = 18.1, 3.5$ Hz, 1H, CH_{2a}(2)), 4.79 (app dt, $J = 18.1, 1.8$ Hz, 1H, CH_{2b}(2)), 5.13 (app d, $J = 3.2$ Hz, 1H, O–CH(7)–O), 6.82 (d, $J = 8.7$ Hz, 2H, CH_{Ar}), 6.96 (dd, $J = 3.0, 1.6$ Hz, 1H, CH(3)), 7.18 (d, $J = 8.7$ Hz, 2H, CH_{Ar}). Characteristic NOESY interactions: CH(7)/CH_{2ax}(6); [CH(5) and OCH_{2a}CH₃]/CH_{2eq}(6); CH_{2ax}(6)/[OCH_{2a}CCl₃, CH(4a), and OCH_{2a}CH₃]; CH_{2ax}(6)/CH_{Ar}. ¹³C NMR (75 MHz, DEPT, HSQC, HMBC, CDCl₃): δ 14.9 (OCH₂CH₃), 33.7 (CH(5)), 34.0 (CH₂(6)), 55.3 (OMe), 63.9 (OCH₂CH₃), 65.3 (CH(4a)), 68.7 (CH₂(2)), 73.8 (OCH₂CCl₃), 94.7 (CCl₃), 100.2 (O–CH(7)–O), 113.7 (CH_{Ar}), 129.5 (CH_{Ar}), 130.3 (C(4)), 131.7 (C_{Ar}), 138.8 (=CH(3)), 158.7 (C_{Ar}–OMe), 162.7 (C=O). HRMS (ESI): m/z calcd. for C₁₉H₂₃Cl₃NO₆⁺ [M + H]⁺: 466.0585, found: 466.0599.

2,2,2-Trichloroethyl (4aR*,5S*,5aR*,9aR*)-5-(4-chlorophenyl)-4a,5,5a,6,7,8,9,9a-octahydro-2H-benzo[e][1,2]oxazino[2,3-b][1,2]oxazine-4-carboxylate **3p**. Nitroso acetal **3p** was obtained from nitronate **1k** (30 mg, 0.11 mmol) and vinyl diazoacetate **2a** (56 mg, 0.23 mmol) according to GP-1 (reaction time = 2 days). Column chromatography (eluent: PE/EtOAc, 40:1) afforded 21 mg of crude nitroso acetal as oil, which was crystallized from PE/CH₂Cl₂, 3:1 to give 8 mg of target nitroso acetal **3p** as white powder. Column chromatography (eluent: PE/CH₂Cl₂, 1:1.5, then 1:2) of filtrate afforded 10 mg of target nitroso acetal **3p** as colorless oil. Total yield: 18 mg (33%). $R_f = 0.47$ (PE/EtOAc, 3:1, UV, anisaldehyde). m.p. = 153–155 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, COSY, CDCl₃, 320 K): δ 1.15–1.38 (m, 4H, CH_{2abcd}), 1.57–1.65 (m, 1H, CH_{2e}), 1.70–1.79 (m, 1H, CH_{2f}), 1.91–2.01 (m, 1H, CH_{2a}(9)), 2.31–2.55 (m, 2H, CH(5a) and CH_{2b}(9)), 3.60 (app t, $J = 9.4$ Hz, 1H, CH(5)–Ar), 4.22–4.45 (m, 4H, CH(4a)–N, CH(5a)–O, and OCH₂CCl₃), 4.59–4.74 (m, 2H, CH₂(2)–O), 6.99 (br s, 1H, CH(3)=), 7.28 (br s, 4H, CH_{Ar}). ¹³C NMR (75 MHz, HSQC, CDCl₃, 320 K): δ 21.5 (br, CH₂), 24.7 (br, CH₂), 27.2 (CH₂), 31.3 (CH₂(9)), 38.5 (CH(5a)), 40.0 (br, CH(5)), 64.5 (br, CH(4a)), 67.1 (br, CH₂(2)), 73.9 (OCH₂CCl₃), 78.8 (br, CH(9a)–O), 94.7 (CCl₃), 128.5 (CH_{Ar}), 129.8 (br, C(4)), 130.5 (br, CH_{Ar}), 132.8 (C_{Ar}), 138.4 (=CH(3)), 162.9 (C=O). C_{Ar} could not be unambiguously identified due to broadening/low intensity/possible overlapping. HRMS (ESI): m/z calcd. for C₂₀H₂₂Cl₄NO₄⁺ [M + H]⁺: 480.0297, found: 480.0286. The crystallographic information for compound **3p** was deposited in the Cambridge Crystallographic Data Centre (CCDC 2242309).

3.3.2. General Procedure for the Synthesis of Pyrrolooxazines **4** (GP-2)

To the 0.3 M solution of nitronate **1** (1 equiv.) in THF, Rh₂(Oct)₄ (0.02 equiv.) was added under an argon atmosphere at r.t. and the mixture was stirred for 5 min. Then THF solution of vinyl diazoacetate **2** (2 equiv. rel. to nitronate **1**, C = 0.5M) was added dropwise (appr. 5–10 min) using a syringe with stirring. The resulting solution was stirred overnight

and evaporated. The residue was dissolved in freshly distilled CH_2Cl_2 (5 mL/1 mmol of starting nitronate **1**). Then 2,2,2-trichloroethanol (10 equiv.) and DBU (2 equiv.) were consequently added under an argon atmosphere. The resulting solution was maintained for 16–24 h (TLC monitoring) and transferred into EtOAc (20 mL)/ H_2O (10 mL). The organic layer was washed with NaHSO_4 (0.5 M in H_2O , 10 mL). Then aqueous layer was washed with EtOAc (10 mL) and the combined layer was washed with brine (15 mL), dried (Na_2SO_4), and evaporated. The residue was preadsorbed onto Celite® and subjected to column chromatography on silica gel (eluent: PE/EtOAc or PE/ CH_2Cl_2) to give target pyrrolooxazines **4**. NB: Even small residual amounts of 2,2,2-trichloroethanol can affect the R_f values of target pyrroles **4** and chromatography rate.

2,2,2-Trichloroethyl 4-(4-methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrrolo[1,2-b][1,2]oxazine-5-carboxylate 4a.

1. To a stirring solution of nitroso acetal **3a** (46 mg, 0.10 mmol) in CH_2Cl_2 (0.50 mL), 2,2,2-trichloroethanol (96 μL , 149 mg, 1.00 mmol) and DBU (30 μL , 30 mg, 0.20 mmol) were consequently added under an argon atmosphere. The resulting solution was stirred for 24 h and transferred into EtOAc (20 mL)/ H_2O (10 mL). The organic layer was washed with NaHSO_4 (0.5 M in H_2O , 10 mL). Then aqueous layer was washed with EtOAc (10 mL) and the combined layer was washed with brine (15 mL), dried (Na_2SO_4), and evaporated. The residue was preadsorbed onto Celite® and subjected to column chromatography on silica gel (eluent: PE/EtOAc, 30:1) to give 32 mg (74%) of the target pyrrolooxazine **4a** as colorless oil, which solidified upon storage in a fridge (ca. 4 °C).

2. (One-pot procedure) Pyrrolooxazine **4a** was obtained from nitronate **1a** (26 mg, 0.11 mmol) and vinyl diazoacetate **2a** (54 mg, 0.22 mmol) according to GP-2. Column chromatography (eluent: PE/EtOAc, 50:1, then 40:1) afforded 29 mg (62%) of the target pyrrolooxazine **4a** as colorless oil. R_f = 0.30 (PE/EtOAc, 5:1, UV, anisaldehyde). m.p. = 93–95 °C (PE/ CH_2Cl_2 , 3:1). ^1H NMR (300 MHz, CDCl_3): δ 1.29 (s, 3H, Me), 1.41 (s, 3H, Me), 2.07 (dd, J = 14.1, 9.2 Hz, 1H, $\text{CH}_{2a}(3)$), 2.32 (dd, J = 14.1, 8.6 Hz, 1H, $\text{CH}_{2b}(3)$), 3.79 (s, 3H, OMe), 4.50 (d, J = 12.0 Hz, 1H, $\text{CO}_2\text{CH}_{2a}\text{CCl}_3$), 4.61 (app t, J = 8.8 Hz, 1H, CH(4)), 4.79 (d, J = 12.0 Hz, 1H, $\text{CO}_2\text{CH}_{2a}\text{CCl}_3$), 6.65 (d, J = 3.2 Hz, 1H, CH(6 or 7)), 6.72 (d, J = 3.2 Hz, 1H, CH(7 or 6)), 6.82 (d, J = 8.7 Hz, 2H, CH_{Ar}), 7.10 (d, J = 8.7 Hz, 2H, CH_{Ar}). ^{13}C NMR (75 MHz, DEPT, CDCl_3): δ 22.5 (Me), 27.1 (Me), 35.6 (CH(4)), 43.3 ($\text{CH}_2(3)$), 55.2 (OMe), 73.1 (OCH_2CCl_3), 82.2 (C(2)), 95.8 (CCl_3), 105.7 (C(5)), 106.5 (CH(6 or 7)), 113.8 (CH_{Ar}), 114.3 (CH(7 or 6)), 128.1 (CH_{Ar}), 129.9 (C(4a)), 136.5 (C_{Ar}), 158.0 (C_{Ar} -OMe), 161.9 (C=O). HRMS (ESI): m/z calcd. for $\text{C}_{19}\text{H}_{21}\text{Cl}_3\text{NO}_4$ $[\text{M} + \text{H}]^+$: 432.0531, found: 432.0520.

2,2,2-Trichloroethyl 4-(4-chloroxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrrolo[1,2-b][1,2]oxazine-5-carboxylate 4g. Pyrrolooxazine **4g** was obtained from nitronate **1b** (27 mg, 0.11 mmol) and vinyl diazoacetate **2a** (54 mg, 0.22 mmol) according to GP-2. Column chromatography (eluent: PE/EtOAc, 40:1) afforded 33 mg (69%) of the target pyrrolooxazine **4g** as white powder. R_f = 0.42 (PE/EtOAc, 5:1, UV, anisaldehyde). m.p. = 111–113 °C (PE/ CH_2Cl_2 , 3:1). ^1H NMR (300 MHz, CDCl_3): δ 1.29 (s, 3H, Me), 1.42 (s, 3H, Me), 2.07 (dd, J = 14.1, 9.4 Hz, 1H, $\text{CH}_{2a}(3)$), 2.33 (dd, J = 14.1, 8.7 Hz, 1H, $\text{CH}_{2b}(3)$), 4.53 (d, J = 12.0 Hz, 1H, $\text{CO}_2\text{CH}_{2a}\text{CCl}_3$), 4.63 (app t, J = 9.0 Hz, 1H, CH(4)), 4.77 (d, J = 12.0 Hz, 1H, $\text{CO}_2\text{CH}_{2b}\text{CCl}_3$), 6.66 (d, J = 3.2 Hz, 1H, CH(6 or 7)), 6.74 (d, J = 3.2 Hz, 1H, CH(7 or 6)), 7.12 (d, J = 8.5 Hz, 2H, CH_{Ar}), 7.26 (d, J = 8.5 Hz, 2H, CH_{Ar}). ^{13}C NMR (75 MHz, DEPT, CDCl_3): δ 22.4 (Me), 27.1 (Me), 35.9 (CH(4)), 43.0 ($\text{CH}_2(3)$), 73.1 (OCH_2CCl_3), 82.1 (C(2)), 95.7 (CCl_3), 105.9 (C(5)), 106.6 (CH(6 or 7)), 114.6 (CH(7 or 6)), 128.5 (CH_{Ar}), 128.6 (CH_{Ar}), 128.8 and 132.0 (C(4a) and C_{Ar}), 142.8 (C_{Ar}), 161.8 (C=O). HRMS (ESI): m/z calcd. for $\text{C}_{18}\text{H}_{17}\text{Cl}_4\text{NNaO}_3$ $[\text{M} + \text{Na}]^+$: 457.9855, found: 457.9862.

2,2,2-Trichloroethyl 4-(benzoyloxy)-2,2-dimethyl-3,4-dihydro-2H-pyrrolo[1,2-b][1,2]oxazine-5-carboxylate 4l. Pyrrolooxazine **4l** was obtained from nitronate **1g** (27 mg, 0.11 mmol) and vinyl diazoacetate **2a** (54 mg, 0.22 mmol) according to GP-2. Column chromatography (eluent: PE/ CH_2Cl_2 , 1:1, then 1:1.5) afforded 12 mg (25%) of the target pyrrolooxazine **4l** as orange oil. R_f = 0.19 (PE/ CH_2Cl_2 , 1:2, UV, anisaldehyde). ^1H NMR (300 MHz, CDCl_3): δ 1.45 (s, 3H, Me), 1.51 (s, 3H, Me), 2.32 (dd, J = 15.3, 3.0 Hz, 1H, $\text{CH}_{2a}(3)$), 2.50 (dd, J = 15.3,

5.9 Hz, 1H, CH_{2b}(3)), 4.61 (d, *J* = 12.0 Hz, 1H, CO₂CH_{2a}CCl₃), 4.94 (d, *J* = 12.0 Hz, 1H, CO₂CH_{2b}CCl₃), 6.64 (dd, *J* = 5.9, 3.0 Hz, 1H, CH(4)), 6.72 (d, *J* = 3.2 Hz, 1H, CH(6 or 7)), 6.79 (d, *J* = 3.2 Hz, 1H, CH(7 or 6)), 7.42 (app t, *J* = 7.6 Hz, 2H, CH_{Bz}), 7.56 (d, *J* = 7.4, 1.3 Hz, 1H, CH_{Bz}), 7.98–8.02 (m, 2H, CH_{Bz}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 23.9 (Me), 26.5 (Me), 38.2 (CH₂(3)), 61.3 (CH(4)), 73.4 (OCH₂CCl₃), 81.1 (C(2)), 95.5 (CCl₃), 107.2 (CH(6 or 7)), 107.9 (C(5)), 115.2 (CH(7 or 6)), 123.5 (C_{Ar}), 128.4 (CH_{Ar}), 129.7 (CH_{Ar}), 130.0 (C(4a)), 133.1 (CH_{Ar}), 161.7 (C=O), 165.5 (C=O). HRMS (ESI): *m/z* calcd. for C₁₉H₁₈Cl₃NNaO₅⁺ [M + Na]⁺: 468.0143, found: 468.0131.

2,2,2-Trichloroethyl 2,2-dimethyl-4-phenethyl-3,4-dihydro-2H-pyrrolo[1,2-*b*][1,2]oxazine-5-carboxylate 4m. Pyrrolooxazine **4m** was obtained from nitronate **1h** (26 mg, 0.11 mmol) and vinyl diazoacetate **2a** (54 mg, 0.22 mmol) according to GP-2. Column chromatography (eluent: PE/EtOAc, 70:1) afforded 27 mg (57%) of the target pyrrolooxazine **4m** as colorless oil. *R_f* = 0.48 (PE/EtOAc, 5:1, UV, anisaldehyde). ¹H NMR (300 MHz, COSY, CDCl₃): δ 1.15 (s, 3H, Me), 1.49 (s, 3H, Me), 1.91–2.04 (m, 2H, PhCH₂CH_{2a} and CH_{2a}(3)), 2.13 (dd, *J* = 13.9, 8.7 Hz, 1H, CH_{2b}(3)), 2.39–2.50 (m, 1H, PhCH₂CH_{2b}), 2.65–2.75 (m, 2H, PhCH₂), 3.58 (app qd, *J* = 8.7, 4.0 Hz, 1H, CH(4)), 4.87–4.95 (m, 2H, OCH₂CCl₃), 6.61–6.64 (m, 2H, CH(6) and CH(7)), 7.17–7.23 (m, 2H, CH_{Ph}), 7.27–7.32 (m, 3H, CH_{Ph}). ¹³C NMR (75 MHz, DEPT, HSQC, CDCl₃): δ 23.0 (Me), 27.6 (Me), 29.6 (CH(4)), 32.9 (PhCH₂), 36.9 (PhCH₂CH₂), 39.0 (CH₂(3)), 73.6 (OCH₂CCl₃), 82.7 (C(2)), 95.8 (CCl₃), 104.9 (C(5)), 106.5 (CH(6 or 7)), 114.4 (CH(7 or 6)), 125.9 and 128.4 (all CH_{Ph}), 132.2 (C(4a)), 141.9 (C_{Ph}), 162.6 (C=O). HRMS (ESI): *m/z* calcd. for C₂₀H₂₃Cl₃NO₃⁺ [M + H]⁺: 430.0738, found: 430.0740.

2,2,2-Trichloroethyl (2*R,4*S**)-2,4-diphenyl-3,4-dihydro-2H-pyrrolo[1,2-*b*][1,2]oxazine-5-carboxylate 4n.** Pyrrolooxazine **4n** was obtained from nitronate **1i** (28 mg, 0.11 mmol) and vinyl diazoacetate **2a** (54 mg, 0.22 mmol) according to GP-2. Column chromatography (eluent: PE/EtOAc, 70:1, then 50:1) afforded 25 mg (50%) of the target pyrrolooxazine **4n** as colorless oil. *R_f* = 0.38 (PE/EtOAc, 5:1, UV, anisaldehyde). ¹H NMR (300 MHz, CDCl₃): δ 2.41 (ddd, *J* = 14.4, 11.8, 9.8 Hz, 1H, CH_{2a}(3)), 2.76 (ddd, *J* = 14.4, 8.9, 1.9 Hz, 1H, CH_{2b}(3)), 4.36 (d, *J* = 12.0 Hz, 1H, CO₂CH_{2a}CCl₃), 4.85 (d, *J* = 12.0 Hz, 1H, CO₂CH_{2b}CCl₃), 4.90 (app t, *J* = 9.2 Hz, 1H, CH(4)), 5.31 (dd, *J* = 11.8, 1.9 Hz, 1H, CH(2)), 6.69 (d, *J* = 3.3 Hz, 1H, CH(6 or 7)), 6.85 (d, *J* = 3.3 Hz, 1H, CH(7 or 6)), 7.20–7.34 (m, 5H, Ph), 7.40–7.46 (m, 5H, Ph). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 38.9 (CH(4)), 39.7 (CH₂(3)), 72.8 (OCH₂CCl₃), 84.2 (CH(2)), 95.8 (CCl₃), 106.2 (C(5)), 106.7 (CH(6 or 7)), 114.0 (CH(7 or 6)), 126.5 (CH_{Ph}), 126.86 (CH_{Ph}), 126.93 (CH_{Ph}), 128.6 (CH_{Ph}), 128.9 (CH_{Ph}), 129.4 (CH_{Ph}), 129.5 (C(4a)), 136.7 (C_{Ph}), 144.5 (C_{Ph}), 161.8 (C=O). HRMS (ESI): *m/z* calcd. for C₂₂H₁₈Cl₃NNaO₃⁺ [M + Na]⁺: 472.0244, found: 472.0234.

2,2,2-Trichloroethyl (2*S,4*S**)-2-ethoxy-4-(4-methoxyphenyl)-3,4-dihydro-2H-pyrrolo[1,2-*b*][1,2]oxazine-5-carboxylate 4o.** Pyrrolooxazine **4o** was obtained from nitronate **1j** (18 mg, 0.07 mmol) and vinyl diazoacetate **2a** (34 mg, 0.14 mmol) according to GP-2. Column chromatography (eluent: PE/EtOAc, 50:1, then 30:1) afforded 15 mg (47%) of the target pyrrolooxazine **4o** as orange oil. *R_f* = 0.31 (PE/EtOAc, 5:1, UV, anisaldehyde). ¹H NMR (300 MHz, CDCl₃): δ 1.22 (t, *J* = 7.1 Hz, 3H, OCH₂CH₃), 2.30–2.47 (m, 2H, CH₂(3)), 3.67 (dq, *J* = 9.7, 7.1 Hz, 1H, OCH_{2a}CH₃), 3.79 (s, 3H, OMe), 3.91 (dq, *J* = 9.7, 7.1 Hz, 1H, OCH_{2b}CH₃), 4.54 (d, *J* = 12.0 Hz, 1H, CO₂CH_{2a}CCl₃), 4.60 (app t, overlapped, *J* = 7.2 Hz, 1H, CH(4)), 4.81 (d, overlapped, *J* = 12.0 Hz, 1H, CO₂CH_{2b}CCl₃), 5.35 (app t, *J* = 4.0 Hz, 1H, O–CH(7)–O), 6.66 (d, *J* = 3.3 Hz, 1H, CH(6 or 7)), 6.73 (d, *J* = 3.3 Hz, 1H, CH(7 or 6)), 6.83 (d, *J* = 8.7 Hz, 2H, CH_{Ar}), 7.09 (d, *J* = 8.6 Hz, 2H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 15.0 (OCH₂CH₃), 34.2 (CH(4)), 36.2 (CH₂(3)), 55.2 (OMe), 65.2 (OCH₂CH₃), 73.2 (OCH₂CCl₃), 95.7 (CCl₃), 102.1 (O–CH(7)–O), 105.6 (C(5)), 106.6 (CH(6 or 7)), 113.9 (CH_{Ar}), 114.1 (CH(7 or 6)), 128.2 (CH_{Ar}), 130.8 (C(4a)), 135.6 (C_{Ar}), 158.1 (C_{Ar}–OMe), 162.0 (C=O). HRMS (ESI): *m/z* calcd. for C₁₉H₂₁Cl₃NO₅⁺ [M + H]⁺: 470.0299, found: 470.0295.

3.3.3. Preparation of Pyrrolooxazines **4b**, **5**

Methyl 4-(4-methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrrolo[1,2-*b*][1,2]oxazine-5-carboxylate 4b. To a stirring solution of nitroso acetal **3a** (31 mg, 0.07 mmol) in a mixture of

MeOH (0.34 mL) and MeCN (0.17 mL), DBU (20 μ L, 20 mg, 0.13 mmol) was added dropwise under an argon atmosphere at r.t. The resulting solution was left overnight and transferred into EtOAc (20 mL)/H₂O (10 mL). The organic layer was washed with NaHSO₄ (0.5 M in H₂O, 10 mL). Then aqueous layer was washed with EtOAc (10 mL) and the combined layer was washed with brine (15 mL), dried (Na₂SO₄), and evaporated. The residue was preadsorbed onto Celite[®] and subjected to column chromatography on silica gel (eluent: PE/EtOAc 20:1, then 12:1) to give 13 mg (60%) of the target pyrrolooxazine **4b** as colorless oil, which solidified upon storage in a fridge (*ca.* 4 °C). *R*_f = 0.29 (PE/EtOAc, 3:1, UV, anisaldehyde). mp = 93–95 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, COSY, CDCl₃): δ 1.25 (s, 3H, Me), 1.41 (s, 3H, Me), 2.05 (dd, *J* = 14.1, 9.5 Hz, 1H, CH_{2a}(3)), 2.28 (dd, *J* = 14.1, 8.7 Hz, 1H, CH_{2b}(3)), 3.51 (s, 3H, CO₂Me), 3.79 (s, 3H, OMe), 4.54 (app t, *J* = 9.1 Hz, 1H, CH(4)), 6.53 (d, *J* = 3.2 Hz, 1H, CH(6 or 7)), 6.68 (d, *J* = 3.2 Hz, 1H, CH(7 or 6)), 6.83 (d, *J* = 8.7 Hz, 2H, CH_{Ar}), 7.10 (d, *J* = 8.7 Hz, 2H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, HSQC, HMBC, CDCl₃): δ 22.2 (Me), 27.2 (Me), 35.8 (CH(4)), 43.6 (CH₂(3)), 50.5 (CO₂Me), 55.2 (C_{Ar}–OMe), 82.0 (C(2)), 105.9 (CH(6 or 7)), 107.4 (C(5)), 113.8 (CH_{Ar}), 113.9 (CH(7 or 6)), 128.0 (CH_{Ar}), 128.7 (C(4a)), 137.2 (C_{Ar}), 157.9 (C_{Ar}–OMe), 164.5 (C=O). HRMS (ESI): *m/z* calcd. for C₁₈H₂₂NO₄⁺ [M + H]⁺: 316.1543, found: 316.1550. The crystallographic information for compound **4b** was deposited in the Cambridge Crystallographic Data Centre (CCDC 2242308).

4-(4-Methoxyphenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrrolo[1,2-b][1,2]oxazine-5-carboxylic acid **5**. To a stirring solution of nitroso acetal **3a** (35 mg, 0.08 mmol) in THF (0.39 mL), *t*-BuONa (15 mg, 0.16 mmol) was added under an argon atmosphere at r.t. The resulting solution was stirred for 0.5 h and transferred into EtOAc (20 mL)/H₂O (10 mL). The organic layer was washed with NaHSO₄ (0.5 M in H₂O, 10 mL). Then aqueous layer was washed with EtOAc (10 mL) and the combined layer was washed with brine (15 mL), dried (Na₂SO₄), and evaporated. The residue was preadsorbed onto Celite[®] and subjected to column chromatography on silica gel (eluent: PE/EtOAc, 20:1, then 5:1, then 3:1) to give 2 mg (6%) of pyrrolooxazine **4a** and 5.5 mg (23%) of the target pyrrolooxazine acid **5** as an oil, which solidified upon storage in a fridge (*ca.* 4 °C) as white powder. *R*_f = 0.28 (PE/EtOAc, 1:1, UV, anisaldehyde). m.p. = 185–187 °C (PE/CH₂Cl₂, 3:1). ¹H NMR (300 MHz, CDCl₃): δ 1.22 (s, 3H, Me), 1.41 (s, 3H, Me), 2.09 (dd, *J* = 14.2, 8.7 Hz, 1H, CH_{2a}(3)), 2.30 (dd, *J* = 14.2, 8.9 Hz, 1H, CH_{2b}(3)), 3.79 (s, 3H, OMe), 4.58 (app t, *J* = 8.8 Hz, 1H, CH(4)), 6.54 (d, *J* = 3.2 Hz, 1H, CH(6 or 7)), 6.68 (d, *J* = 3.2 Hz, 1H, CH(7 or 6)), 6.81 (d, *J* = 8.7 Hz, 2H, CH_{Ar}), 7.09 (d, *J* = 8.7 Hz, 2H, CH_{Ar}). ¹³C NMR (75 MHz, DEPT, CDCl₃): δ 22.5 (Me), 27.2 (Me), 35.5 (CH(4)), 43.4 (CH₂(3)), 55.2 (OMe), 82.5 (C(2)), 106.4 (C(5)), 106.5 (CH(6 or 7)), 113.8 (CH_{Ar}), 114.3 (CH(7 or 6)), 128.3 (CH_{Ar}), 130.3 (C(4a)), 136.8 (C_{Ar}), 157.9 (C_{Ar}–OMe), 168.3 (C=O). HRMS (ESI): *m/z* calcd. for C₁₇H₂₀NO₄⁺ [M + H]⁺: 302.1384, found: 302.1390.

4. Conclusions

In conclusion, an approach was developed for the synthesis of bicyclic nitroso acetals (4a,5,6,7-tetrahydro-2H-[1,2]oxazino[2,3-b][1,2]oxazines) via an Rh(II)-catalyzed annulation of six-membered cyclic nitronates with vinyl diazoacetates. Target products were obtained in good yields with excellent diastereoselectivity. These nitroso acetals undergo smooth ring contraction under the action of the DBU/alcohol system. Combined with a [3+3]-annulation in a one-pot protocol, it represents a quick approach to the assembly of pyrrolooxazines and complements already known approaches to this relatively rare heterocyclic core.

Supplementary Materials: The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/molecules28073025/s1>, Table S1: Preparation of starting compounds, crystal data, optimization, Tables S2 and S3: Tables for the synthesis of pyrrolooxazines **4a** and **4b**, Copies of NMR spectra.

Author Contributions: Conceptualization, Y.A.A. and A.A.T.; methodology, Y.A.A. and A.A.T.; validation, Y.A.A., Y.V.N. and A.A.T.; formal analysis, Y.A.A., Y.V.N. and A.A.T.; investigation, Y.A.A. and Y.V.N.; data curation, Y.A.A.; writing—original draft preparation, Y.A.A. and A.A.T.; writing—

review and editing, A.A.T. and S.L.I.; supervision, A.A.T.; project administration, A.A.T.; funding acquisition, A.A.T. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the Russian Science Foundation (grant 21-73-10011). X-ray diffraction data were collected using the equipment of the Center for Molecular Composition Studies of INEOS RAS with financial support from the Ministry of Science and Higher Education of the Russian Federation (Contract/agreement No. 075-03-2023-642).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in this article and in the Supplementary Materials.

Acknowledgments: The authors thank N.G. Kolotyrykina and A.O. Chizhov (N. D. Zelinsky Institute of Organic Chemistry) for registration of HRMS.

Conflicts of Interest: The authors declare no conflict of interest.

Sample Availability: Samples of the compounds are not available from the authors.

References

1. Majireck, M.M.; Bennett, J.M. 1,2-Oxazines and their benzo derivatives. In *Comprehensive Heterocyclic Chemistry IV*; Weinreb, S.M., Black, D.S.C., Cossy, J., Stevens, C.V., Eds.; Elsevier Ltd.: Amsterdam, The Netherlands, 2022; Volume 8, pp. 283–415. [\[CrossRef\]](#)
2. Ghosh, P.; Mondal, S.L.; Baidya, M. Ascending of cycloaddition strategy for N–O heterocycles. *Synthesis* **2022**, *54*, 1043–1054. [\[CrossRef\]](#)
3. Sukhorukov, A.Y.; Ioffe, S.L. Chemistry of six-membered cyclic oxime ethers. Application in the synthesis of bioactive compounds. *Chem. Rev.* **2011**, *111*, 5004–5041. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Utecht, G.; Jasinski, M. 3,6-Dihydro-2H-1,2-oxazines (microreview). *Chem. Heterocycl. Compd.* **2016**, *52*, 143–145. [\[CrossRef\]](#)
5. Brulikova, L.; Harrison, A.; Miller, M.J.; Hlavac, J. Stereo- and regioselectivity of the hetero-Diels–Alder reaction of nitroso derivatives with conjugated dienes. *Beilstein J. Org. Chem.* **2016**, *12*, 1949–1980. [\[CrossRef\]](#) [\[PubMed\]](#)
6. Bouche, L.; Reissig, H.-U. Synthesis of novel carbohydrate mimetics via 1,2-oxazines. *Pure Appl. Chem.* **2012**, *84*, 23–36. [\[CrossRef\]](#)
7. Bodnar, B.S.; Miller, M.J. The nitrosocarbonyl hetero-Diels–Alder reaction as a useful tool for organic syntheses. *Angew. Chem. Int. Ed.* **2011**, *50*, 5630–5647. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Pfrengle, F.; Reissig, H.-U. Amino sugars and their mimetics via 1,2-oxazines. *Chem. Soc. Rev.* **2010**, *39*, 549–557. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Gu, Z.; Saito, T.; Zakarian, A. Approaches to dihydrooxazine ring systems and application in the synthesis of bioactive natural products. *Chem. Heterocycl. Compd.* **2012**, *48*, 11–16. [\[CrossRef\]](#)
10. Wehlauch, R.; Gadermann, K. Securinega alkaloids: Complex structures, potent bioactivities, and efficient total syntheses. *Asian J. Org. Chem.* **2017**, *6*, 1146–1159. [\[CrossRef\]](#)
11. Ohta, S.; Oshimo, S.; Ohta, E.; Nehira, T.; Omura, H.; Uy, M.M.; Ishihara, Y. Asaroidoxazines from the roots of *Asarum asaroides* induce apoptosis in human neuroblastoma cells. *J. Nat. Prod.* **2020**, *83*, 3050–3057. [\[CrossRef\]](#)
12. Liu, C.; Yang, C.; Zeng, Y.; Shi, J.; Li, L.; Li, W.; Jiao, R.; Tan, R.; Ge, H. Chartrenoline, a novel alkaloid isolated from a marine *Streptomyces chartreusis* NA02069. *Chin. Chem. Lett.* **2019**, *30*, 44–46. [\[CrossRef\]](#)
13. Li, J.; Hu, Y.; Hao, X.; Tan, J.; Li, F.; Qiao, X.; Chen, S.; Xiao, C.; Chen, M.; Peng, Z.; et al. Raistrickindole A, an anti-HCV oxazinoindole alkaloid from *Penicillium raistrickii* IMB17-034. *J. Nat. Prod.* **2019**, *82*, 1391–1395. [\[CrossRef\]](#)
14. Wu, Z.-L.; Huang, X.-J.; Xu, M.-T.; Ma, X.; Li, L.; Shi, L.; Wang, W.-J.; Jiang, R.-W.; Ye, W.-C.; Wang, Y. Flueggeacosines A–C, dimeric securinine-type alkaloid analogues with neuronal differentiation activity from *Flueggea suffruticosa*. *Org. Lett.* **2018**, *20*, 7703–7707. [\[CrossRef\]](#)
15. Kim, Y.; In, Y.; Ishida, T.; Onaka, H.; Igarashi, Y. Biosynthetic origin of alchivemycin A, a new polyketide from *Streptomyces* and absolute configuration of alchivemycin B. *Org. Lett.* **2013**, *15*, 3514–3517. [\[CrossRef\]](#)
16. Koyama, K.; Hirasawa, Y.; Nugroho, A.E.; Hosoya, T.; Hoe, T.C.; Chan, K.-L.; Morita, H. Alsmaphorazines A and B, novel indole alkaloids from *Alstonia pneumatophora*. *Org. Lett.* **2010**, *12*, 4188–4191. [\[CrossRef\]](#)
17. Shao, C.-L.; Wang, C.-Y.; Gu, Y.-C.; Cai, J.-W.; Deng, D.-S.; She, Z.-G.; Lin, Y.-C. Revised structure of penicillazine and preparation, bioactivities of penicillazine derivatives. *Lett. Org. Chem.* **2009**, *6*, 387–391. [\[CrossRef\]](#)
18. Garo, E.; Starks, C.M.; Jensen, P.R.; Fenical, W.; Lobkovsky, E.; Clardy, J. Trichodermamides A and B, cytotoxic modified dipeptides from the marine-derived fungus *Trichoderma virens*. *J. Nat. Prod.* **2003**, *66*, 423–426. [\[CrossRef\]](#)
19. Mfuh, A.M.; Zhang, Y.; Stephens, D.E.; Vo, A.X.T.; Arman, H.D.; Larionov, O.V. Concise total synthesis of trichodermamides A, B and C enabled by an efficient construction of the 1,2-oxazadecaline core. *J. Am. Chem. Soc.* **2015**, *137*, 8050–8053. [\[CrossRef\]](#) [\[PubMed\]](#)

20. Lambert, K.M.; Cox, J.B.; Liu, L.; Jackson, A.C.; Yruegas, S.; Wiberg, K.B.; Wood, J.L. Total synthesis of (±)-phyllantidine: Development and mechanistic evaluation of a novel ring expansion for installation of embedded nitrogen-oxygen bonds. *Angew. Chem. Int. Ed.* **2020**, *59*, 9757–9766. [\[CrossRef\]](#)
21. Doens, D.; Valiente, P.A.; Mfuh, A.M.; Vo, A.X.T.; Tristan, A.; Carreno, L.; Quijada, M.; Nguyen, V.T.; Perry, G.; Larionov, O.V.; et al. Identification of inhibitors of CD36-amyloid beta binding as potential agents for Alzheimer's disease. *ACS Chem. Neurosci.* **2017**, *8*, 1232–1241. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Jans, P.E.; Mfuh, A.M.; Arman, H.D.; Shaffer, C.V.; Larionov, O.V.; Mooberry, S.L. Cytotoxicity and mechanism of action of the marine-derived fungal metabolite trichodermamide B and synthetic analogues. *J. Nat. Prod.* **2017**, *80*, 676–683. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Pham, T.L.; Sae-Lao, P.; Toh, H.H.M.; Csokas, D.; Bates, R.W. The total synthesis of raistrickindole A. *J. Org. Chem.* **2022**, *87*, 16111–16114. [\[CrossRef\]](#)
24. Li, T.-Z.; Liu, S.-J.; Sun, Y.-W.; Deng, S.; Tan, W.; Jiao, Y.; Zhang, Y.-C.; Shi, F. Regio- and enantioselective (3+3) cycloaddition of nitrones with 2-indolylmethanols enabled by cooperative organocatalysis. *Angew. Chem. Int. Ed.* **2021**, *60*, 2355–2363. [\[CrossRef\]](#) [\[PubMed\]](#)
25. Herrera, L.; Stephens, D.E.; D'Avila, A.; George, K.G.; Arman, H.; Zhang, Y.; Perry, G.; Lleonart, R.; Larionov, O.V.; Fernandez, P.L. Insights into the structural patterns of the antileishmanial activity of bi- and tricyclic N-heterocycles. *Org. Biomol. Chem.* **2016**, *14*, 7053–7060. [\[CrossRef\]](#) [\[PubMed\]](#)
26. Yang, B.; Zollner, T.; Gebhardt, P.; Mollmann, U.; Miller, M.J. Preparation and biological evaluation of novel leucomycin analogs derived from nitroso Diels-Alder reactions. *Org. Biomol. Chem.* **2010**, *8*, 691–697. [\[CrossRef\]](#)
27. Tabolin, A.A.; Sukhorukov, A.Y.; Ioffe, S.L.; Dilman, A.D. Recent advances in the synthesis and chemistry of nitronates. *Synthesis* **2017**, *49*, 3255–3268. [\[CrossRef\]](#)
28. Denmark, S.E.; Thorarensen, A. Tandem [4+2]/[3+2] cycloadditions of nitroalkenes. *Chem. Rev.* **1996**, *96*, 137–166. [\[CrossRef\]](#)
29. Ioffe, S.L. Nitronates. In *Nitrile Oxides, Nitrones, and Nitronates in Organic Synthesis, Novel Strategies in Synthesis*, 2nd ed.; Feuer, H., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2008; pp. 541–604.
30. Baiazitov, R.Y.; Denmark, S.E. Tandem [4+2]/[3+2] Cycloadditions. In *Methods and Applications of Cycloaddition Reactions in Organic Syntheses*; Nishiwaki, N., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2014; pp. 471–550.
31. Denmark, S.E.; Cottell, J.J. Nitronates. In *The Chemistry of Heterocyclic Compounds: Synthetic Applications of 1,3-Dipolar Cycloaddition Chemistry toward Heterocycles and Natural Products*; Padwa, A., Pearson, W.H., Eds.; Wiley-Interscience: New York, NY, USA, 2002; pp. 83–167.
32. Denmark, S.E.; Cottell, J.J. Synthesis of (+)-1-epiaustraline. *J. Org. Chem.* **2001**, *66*, 4276–4284. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Denmark, S.E.; Hurd, A.R. Synthesis of (+)-casuarine. *J. Org. Chem.* **2000**, *65*, 2875–2886. [\[CrossRef\]](#)
34. Denmark, S.E.; Martinborough, E.A. Enantioselective total syntheses of (+)-castanospermine, (+)-6-epicastanospermine, (+)-australine, and (+)-3-epiaustraline. *J. Am. Chem. Soc.* **1999**, *121*, 3046–3056. [\[CrossRef\]](#)
35. Denmark, S.E.; Herbert, B. Synthesis of (1R,2R,3R,7R,7aR)-hexahydro-3-(hydroxymethyl)-1H-pyrrolizine-1,2,7-triol: 7-epiaustraline. *J. Am. Chem. Soc.* **1998**, *120*, 7357–7358. [\[CrossRef\]](#)
36. Denmark, S.E.; Hurd, A.R.; Sacha, H.J. Tandem [4+2]/[3+2] cycloadditions of nitroalkenes. 13. The synthesis of (–)-detoxinine. *J. Org. Chem.* **1997**, *62*, 1668–1674. [\[CrossRef\]](#)
37. Denmark, S.E.; Marcin, L.R. Asymmetric construction of a quaternary carbon center by tandem [4+2]/[3+2] cycloaddition of a nitroalkene. The total synthesis of (–)-mesembrine. *J. Org. Chem.* **1997**, *62*, 1675–1686. [\[CrossRef\]](#)
38. Denmark, S.E.; Thorarensen, A. Tandem [4+2]/[3+2] cycloadditions of nitroalkenes. 11. The synthesis of (+)-crotanecine. *J. Am. Chem. Soc.* **1997**, *119*, 125–137. [\[CrossRef\]](#)
39. Denmark, S.E.; Thorarensen, A.; Middleton, D.S. Tandem [4+2]/[3+2] cycloadditions of nitroalkenes. 9. Synthesis of (–)-rosmarinine. *J. Am. Chem. Soc.* **1996**, *118*, 8266–8277. [\[CrossRef\]](#)
40. Gorbacheva, E.O.; Tabolin, A.A.; Novikov, R.A.; Khomutova, Y.A.; Nelyubina, Y.V.; Tomilov, Y.V.; Ioffe, S.L. Six-membered cyclic nitronates as 1,3-dipoles in formal [3+3]-cycloaddition with donor-acceptor cyclopropanes. Synthesis of new type of bicyclic nitrosoacetals. *Org. Lett.* **2013**, *15*, 350–353. [\[CrossRef\]](#) [\[PubMed\]](#)
41. Tabolin, A.A.; Gorbacheva, E.O.; Novikov, R.A.; Khoroshutina, Y.A.; Nelyubina, Y.V.; Ioffe, S.L. Synthesis and chemical transformations of six/six-membered bicyclic nitroso acetals. *Russ. Chem. Bull.* **2016**, *65*, 2243–2259. [\[CrossRef\]](#)
42. Cheng, Q.-Q.; Yu, Y.; Yedoyan, J.; Doyle, M.P. Vinyl diazo reagents and metal catalysts: A versatile toolkit for heterocycle and carbocycle construction. *ChemCatChem* **2018**, *10*, 488–496. [\[CrossRef\]](#)
43. Xu, X.-F.; Doyle, M.P. Divergent pathways of β,γ -unsaturated α -diazocarbonyl compounds catalyzed by dirhodium and Lewis acids catalysts separately or in combination. *Chin. Chem. Lett.* **2015**, *26*, 227–232. [\[CrossRef\]](#)
44. Xu, Y.; Wang, Z.; Sun, J. Asymmetric [3+1]-cycloaddition reaction via diazo discrimination. *Org. Lett.* **2021**, *23*, 7613–7617. [\[CrossRef\]](#) [\[PubMed\]](#)
45. Barluenga, J.; Riesgo, L.; Lopez, L.A.; Rubio, E.; Tomas, M. Discrimination of diazo compounds toward carbenoids: Copper(I)-catalyzed synthesis of substituted cyclobutenes. *Angew. Chem. Int. Ed.* **2009**, *48*, 7569–7572. [\[CrossRef\]](#) [\[PubMed\]](#)

46. Dong, K.; Xu, X.; Doyle, M.P. Copper(I)-catalyzed highly enantioselective [3+3]-cycloaddition of γ -alkyl enoldiazoacetates with nitrones. *Org. Chem. Front.* **2020**, *7*, 1653–1657. [\[CrossRef\]](#)
47. Barluenga, J.; Lonzi, G.; Riesgo, L.; Lopez, L.A.; Tomas, M. Pyridine activation via copper(I)-catalyzed annulation toward indolizines. *J. Am. Chem. Soc.* **2010**, *132*, 13200–13202. [\[CrossRef\]](#)
48. Thompson, J.L.; Davies, H.M.L. Enhancement of cyclopropanation chemistry in the silver-catalyzed reactions of aryldiazoacetates. *J. Am. Chem. Soc.* **2007**, *129*, 6090–6091. [\[CrossRef\]](#)
49. Ueda, J.; Harada, S.; Nakayama, H.; Nemoto, T. Silver-catalyzed regioselective hydroamination of alkenyl diazoacetates to synthesize γ -amino acid equivalents. *Org. Biomol. Chem.* **2018**, *16*, 4675–4682. [\[CrossRef\]](#)
50. Xu, G.; Liu, K.; Dai, Z.; Sun, J. Gold/silver-catalyzed controllable regioselective vinylcarbene insertion into O–H bonds. *Org. Biomol. Chem.* **2017**, *15*, 2345–2348. [\[CrossRef\]](#) [\[PubMed\]](#)
51. Pagar, V.V.; Liu, R.-S. Gold-catalyzed α -furanylations of quinoline N-oxides with alkenyldiazo carbonyl species. *Org. Biomol. Chem.* **2015**, *13*, 6166–6169. [\[CrossRef\]](#)
52. Zhou, P.-X.; Zhou, Z.-Z.; Chen, Z.-S.; Ye, Y.-Y.; Zhao, L.-B.; Yang, Y.-F.; Xia, X.-F.; Luo, J.-Y.; Liang, Y.-M. Palladium-catalyzed insertion of α -diazocarbonyl compounds for the synthesis of cyclic amino esters. *Chem. Commun.* **2013**, *49*, 561–563. [\[CrossRef\]](#) [\[PubMed\]](#)
53. Guptill, D.M.; Davies, H.M.L. 2,2,2-Trichloroethyl aryldiazoacetates as robust reagents for the enantioselective C–H functionalization of methyl ethers. *J. Am. Chem. Soc.* **2014**, *136*, 17718–17721. [\[CrossRef\]](#)
54. Negretti, S.; Cohen, C.M.; Chang, J.J.; Guptill, D.M.; Davies, H.M.L. Enantioselective dirhodium(II)-catalyzed cyclopropanations with trimethylsilyl ethyl and trichloroethyl aryldiazoacetates. *Tetrahedron* **2015**, *71*, 7415–7420. [\[CrossRef\]](#)
55. Shved, A.S.; Tabolin, A.A.; Novikov, R.A.; Nelyubina, Y.V.; Timofeev, V.P.; Ioffe, S.L. Six-membered cyclic nitroso acetals: Synthesis and studies of the nitrogen inversion process of N-silyloxy-3,6-dihydro-2H-1,2-oxazines. *Eur. J. Org. Chem.* **2016**, *2016*, 5569–5578. [\[CrossRef\]](#)
56. Ueda, Y.; Roberge, G.; Vinet, V. A simple method of preparing trimethylsilyl- and tert-butyldimethylsilyl-enol ethers of α -diazoacetoacetates and their use in the synthesis of a chiral precursor to thienamycin analogs. *Can. J. Chem.* **1984**, *62*, 2936–2940. [\[CrossRef\]](#)
57. Davies, H.M.L.; Hu, B.; Saikali, E.; Bruzinski, P.R. Carbenoid versus vinylogous reactivity in rhodium(II)-stabilized vinylcarbenoids. *J. Org. Chem.* **1994**, *59*, 4535–4541. [\[CrossRef\]](#)
58. Crocetti, L.; Floresta, G.; Cilibrizzi, A.; Giovannoni, M.P. An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022. *Molecules* **2022**, *27*, 4964. [\[CrossRef\]](#) [\[PubMed\]](#)
59. Dyke, H.J.; Montana, J.G. Update on the therapeutic potential of PDE4 inhibitors. *Expert Opin. Investig. Drugs* **2002**, *11*, 1–13. [\[CrossRef\]](#) [\[PubMed\]](#)
60. Nelyubina, Y.V.; Lyssenko, K.A. Probing stereoelectronic interactions in an O–N–O unit by the atomic energies: Experimental and theoretical electron density study. *J. Phys. Chem. A* **2013**, *117*, 3084–3092. [\[CrossRef\]](#)
61. Tishkov, A.A.; Lesiv, A.V.; Khomutova, Y.A.; Strelenko, Y.A.; Nesterov, I.D.; Antipin, M.Y.; Ioffe, S.L.; Denmark, S.E. 2-Silyloxy-1,2-oxazines, a new type of acetals of conjugated nitroso alkenes. *J. Org. Chem.* **2003**, *68*, 9477–9480. [\[CrossRef\]](#)
62. Zheng, H.; Faghihi, I.; Doyle, M.P. Copper(I)-catalyzed highly enantioselective [3+3]-cycloaddition of β -aryl/alkyl vinyl diazoacetates with nitrones. *Helvetica Chim. Acta* **2021**, *104*, e2100081. [\[CrossRef\]](#)
63. Wang, X.; Abrahams, Q.M.; Zavalij, P.Y.; Doyle, M.P. Highly regio- and stereoselective dirhodium vinylcarbene induced nitron cycloaddition with subsequent cascade carbenoid aromatic cycloaddition/N–O cleavage and rearrangement. *Angew. Chem. Int. Ed.* **2012**, *51*, 5907–5910. [\[CrossRef\]](#)
64. Qin, C.; Davies, H.M.L. Rh₂(R-TPCP)₄-catalyzed enantioselective [3+2]-cycloaddition between nitrones and vinyldiazoacetates. *J. Am. Chem. Soc.* **2013**, *135*, 14516–14519. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Pagar, V.V.; Liu, R.-S. Gold-catalyzed cycloaddition reactions of ethyl diazoacetate, nitrosoarenes, and vinyldiazo carbonyl compounds: Synthesis of isoxazolidine and benzo[b]azepine derivatives. *Angew. Chem. Int. Ed.* **2015**, *54*, 4923–4926. [\[CrossRef\]](#)
66. Stefkova, K.; Guerzoni, M.G.; van Ingen, Y.; Richards, E.; Melen, R.L. B(C₆F₅)₃-catalyzed diastereoselective and divergent reactions of vinyldiazo esters with nitrones: Synthesis of highly functionalized diazo compounds. *Org. Lett.* **2023**, *25*, 500–505. [\[CrossRef\]](#)
67. Humenny, W.J.; Kyriacou, P.; Sapeta, K.; Karadeolian, A.; Kerr, M.A. Multicomponent synthesis of pyrroles from cyclopropanes: A one-pot palladium(0)-catalyzed dehydrocarbonylation/dehydration. *Angew. Chem. Int. Ed.* **2012**, *51*, 11088–11091. [\[CrossRef\]](#) [\[PubMed\]](#)
68. Firl, J.; Kresze, G. Heterocyclen durch Diensynthese, III. Pyrrole, α -Pyrone und Pyridone aus Diels-Alder-Addukten von Nitrosoverbindungen. *Chem. Ber.* **1966**, *99*, 3695–3706. [\[CrossRef\]](#)
69. Firl, J. Heterocyclen durch Diensynthese, Pyridylpyrrole aus Diels-Alder-Addukten von Nitrosoverbindungen. *Chem. Ber.* **1968**, *101*, 218–225. [\[CrossRef\]](#)
70. Kefalas, P.; Grierson, D.S. Synthesis of pyrrolo-castanospermine analogs: A novel fluoride ion induced rearrangement of a 3-trialkylsilyl substituted dihydro-2H-1,2-oxazine to a pyrrole. *Tetrahedron Lett.* **1993**, *34*, 3555–3558. [\[CrossRef\]](#)

71. Eberlin, L.; Carboni, B.; Whiting, A. Regioisomeric and substituent effects upon the outcome of the reaction of 1-borodienes with nitrosoarene compounds. *J. Org. Chem.* **2015**, *80*, 6574–6583. [\[CrossRef\]](#)
72. Yasukawa, N.; Kuwata, M.; Imai, T.; Monguchi, Y.; Sajiki, H.; Sawama, Y. Copper-catalyzed pyrrole synthesis from 3,6-dihydro-1,2-oxazines. *Green Chem.* **2018**, *20*, 4409–4413. [\[CrossRef\]](#)
73. Jasinski, M.; Watanabe, T.; Reissig, H.-U. Samarium diiodide promoted reduction of 3,6-dihydro-2H-1,2-oxazines: Competition of 1,4-amino alcohol formation and ring contraction to pyrrole derivatives. *Eur. J. Org. Chem.* **2013**, *2013*, 605–610. [\[CrossRef\]](#)
74. Scheiner, P.; Chapman, O.L.; Lassila, J.D. The photolysis of dihydro-1,2-oxazines. *J. Org. Chem.* **1969**, *34*, 813–816. [\[CrossRef\]](#)
75. Givens, R.S.; Choo, D.J.; Merchant, S.N.; Stitt, R.P.; Matuszewski, B. Photochemistry of 3,6-dihydro-1,2-oxazines: A versatile route to substituted pyrroles. *Tetrahedron Lett.* **1982**, *23*, 1327–1330. [\[CrossRef\]](#)
76. Rudchenko, V.F. Synthesis, reactions, and properties of oxygen-nitrogen-oxygen systems. *Chem. Rev.* **1993**, *93*, 725–739. [\[CrossRef\]](#)
77. Lukoyanov, A.A.; Tabolin, A.A.; Nelyubina, Y.V.; Ioffe, S.L.; Sukhorukov, A.Y. Deoxygenative arylation of 5,6-dihydro-4H-1,2-oxazine-N-oxides with arynes. *J. Org. Chem.* **2022**, *87*, 6838–6851. [\[CrossRef\]](#)
78. Kumar, P.; Kumar, R.; Banerjee, P. Accessing dihydro-1,2-oxazine via Cloke–Wilson-type annulation of cyclopropyl carbonyls: Application toward the diastereoselective synthesis of pyrrolo [1,2-b][1,2]oxazine. *J. Org. Chem.* **2020**, *85*, 6535–6550. [\[CrossRef\]](#)
79. Jasinski, M.; Moreno-Clavijo, E.; Reissig, H.-U. Synthesis of a series of enantiopure polyhydroxylated bicyclic N-heterocycles from an L-erythrose-derived nitron and alkoxyallenes. *Eur. J. Org. Chem.* **2014**, *2014*, 442–454. [\[CrossRef\]](#)
80. Mondal, S.K.; Ali, S.A.; Manna, S.K.; Mandal, A.; Senapati, B.K.; Hossain, M.; Samanta, S. Palladium-catalyzed intramolecular cyclization: Access to rare pentacyclic N-fused heterocycles. *ChemistrySelect* **2017**, *2*, 9312–9318. [\[CrossRef\]](#)
81. Diab, S.; Noel-Duchesneau, L.; Sanselme, M.; Kondo, Y.; De Paolis, M.; Chataigner, I. High pressure elicits unexpected transformations of plain nitroaromatics with 4-(cyclohex-1-en-1-yl)morpholine. *Eur. J. Org. Chem.* **2018**, *2018*, 2048–2052. [\[CrossRef\]](#)
82. Xu, C.; Du, J.; Ma, L.; Li, G.; Tao, M.; Zhang, W. Tertiary amine functionalized polyacrylonitrile fiber catalyst for the synthesis of tetrahydrothiophenes. *Tetrahedron* **2013**, *69*, 4749–4757. [\[CrossRef\]](#)
83. Ramirez-Osuna, M.; Chavez, D.; Hernandez, L.; Mollins, E.; Somanathan, R.; Aguirre, G. Synthesis of analogs of amathamide A and their preliminary antimicrobial activity. *Molecules* **2005**, *10*, 295–301. [\[CrossRef\]](#)
84. Jakubec, P.; Cockfield, D.M.; Hynes, P.S.; Cleator, E.; Dixon, D.J. Enantio- and diastereoselective Michael additions of C-succinimidyl esters to nitro olefins using cinchonine-derived bifunctional organocatalysts. *Tetrahedron Asym.* **2011**, *22*, 1147–1155. [\[CrossRef\]](#)
85. Wen, L.; Tang, F.; Ge, C.; Wang, X.; Han, Z.; Wu, J. Practical large-scale preparation of (R)-rolipram using chiral nickel catalyst. *Synth. Commun.* **2012**, *42*, 3288–3295. [\[CrossRef\]](#)
86. Fadeeva, A.A.; Ioffe, S.L.; Tabolin, A.A. Chlorination of conjugated nitroalkenes with PhICl_2 and SO_2Cl_2 for the synthesis of α -chloronitroalkenes. *Synthesis* **2020**, *52*, 2679–2688. [\[CrossRef\]](#)
87. Smirnov, V.O.; Ioffe, S.L.; Tishkov, A.A.; Khomutova, Y.A.; Nesterov, I.D.; Antipin, M.Y.; Smit, W.A.; Tartakovsky, V.A. New C-C coupling reaction of cyclic nitronates with carbon nucleophiles. Umpolung of the conventional reactivity of nitronates. *J. Org. Chem.* **2004**, *69*, 8485–8488. [\[CrossRef\]](#) [\[PubMed\]](#)
88. Ushakov, P.Y.; Tabolin, A.A.; Ioffe, S.L.; Sukhorukov, A.Y. In situ generated magnesium cyanide as an efficient reagent for nucleophilic cyanation of nitrosoalkenes and parent nitronates. *Eur. J. Org. Chem.* **2019**, *2019*, 1888–1892. [\[CrossRef\]](#)
89. Mikhaylov, A.A.; Dilman, A.D.; Khomutova, Y.A.; Arkhipov, D.E.; Korlyukov, A.A.; Ioffe, S.L. Stereoselective amine addition to six-membered cyclic nitronates promoted by silyl triflate. *Eur. J. Org. Chem.* **2013**, *2013*, 5670–5677. [\[CrossRef\]](#)
90. Davies, H.M.L.; Hougland, P.W.; Cantrell, W.R., Jr. Convenient Synthesis of Vinyldiazomethanes from α -Diazo- β -Keto Esters and Related Systems. *Synth. Commun.* **1992**, *22*, 971–978. [\[CrossRef\]](#)
91. Wu, J.-Q.; Yang, Z.; Zhang, S.-S.; Jiang, C.-Y.; Li, Q.; Huang, Z.-S.; Wang, H. From indoles to carbazoles: Tandem $\text{Cp}^*\text{Rh(III)}$ -catalyzed C–H activation/Brønsted acid-catalyzed cyclization reactions. *ACS Catal.* **2015**, *5*, 6453–6457. [\[CrossRef\]](#)
92. Korte, F.; Wusten, F. Über den Enolgehalt von Acetessigsäureestern mit verschiedenen Esteralkyl-Komponenten. *Justus Liebigs Ann. Chem.* **1961**, *647*, 18–22. [\[CrossRef\]](#)
93. Dolle, F.; Hinnen, F.; Valette, H.; Fuseau, C.; Duval, R.; Peglion, J.-L.; Crouzel, C. Synthesis of two optically active calcium channel antagonists labelled with carbon-11 for in vivo cardiac PET imaging. *Bioorg. Med. Chem. Lett.* **1997**, *5*, 749–764. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Hansen, J.; Li, B.; Dikarev, E.; Autschbach, J.; Davies, H.M.L. Combined experimental and computational studies of hetero-bimetallic Bi–Rh paddlewheel carboxylates as catalysts for metal carbenoid transformations. *J. Org. Chem.* **2009**, *74*, 6564–6571. [\[CrossRef\]](#)
95. Chinthapally, K.; Massaro, N.P.; Ton, S.; Gardner, E.D.; Sharma, I. Trapping rhodium vinylcarbenoids with aminochalcones for the synthesis of medium-sized azacycles. *Tetrahedron Lett.* **2019**, *60*, 151253. [\[CrossRef\]](#)
96. Rossbach, J.; Baumeister, J.; Harms, K.; Koert, U. Regio- and diastereoselective crotylboration of *vic*-tricarboxyl compounds. *Eur. J. Org. Chem.* **2013**, *2013*, 662–665. [\[CrossRef\]](#)
97. Sarabia, F.J.; Li, Q.; Ferreira, E.M. Cyclopentene annulations of alkene radical cations with vinyl diazo species using photocatalysis. *Angew. Chem. Int. Ed.* **2018**, *57*, 11015–11019. [\[CrossRef\]](#)
98. Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. *Acta Crystallogr. Sect. A* **2015**, *71*, 3–8. [\[CrossRef\]](#) [\[PubMed\]](#)

99. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program. *J. Appl. Cryst.* **2009**, *42*, 339–341. [[CrossRef](#)]
100. Sheldrick, G.M. A short history of SHELX. *Acta Crystallogr. Sect. A* **2008**, *A64*, 112–122. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.